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  More than 40 million people are living with human immunodeficiency virus-1 (HIV-1). 
A prophylactic vaccine inducing a ‘sterilizing immunity’ is desired to prevent further infections, 
but will require many years to develop.  Moreover, prophylactic vaccines will not help the 
millions of people who are already infected with the virus, and who face life-long treatment with 
expensive and toxic antiretroviral therapy (ART). This dissertation is based on the proposal that 
the best strategy for these individuals is  a therapeutic vaccine  that will attack residual viral 
reservoirs by expanding  HIV-1 specific, primary T cell responses to the persons’s own, 
autologous virus.  
Previously, this laboratory demonstrated that mature dendritic cells (DC) loaded with 
immunodominant HIV-1 peptides or HIV-1 infected apoptotic bodies can activate residual HIV-
1 specific memory T cell responses. However, such memory T cells are only partially restored 
during ART. I hypothesized that targeting naive CD8+ T cells through a DC-based 
immunotherapy could elicit a robust and broad T cell response to HIV-1. Furthermore, most 
immunotherapy studies have used consensus strains of HIV-1 antigens that I believe 
inadequately represent the host’s diverse pool of HIV-1 quasispecies. The current study has 
provided initial data that support that CD8+ T cells can be primed by in vitro engineered DC, 
even against autologous HIV-1 peptides representing immune escape variants. This study 
therefore supports the concept of using autologous virus as an antigen in immunotherapy and 
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demonstrates that the use of autologous viral sequences expands both memory and primary T cell 
responses in vitro. Thus, a potential advantage is that future immunotherapies could use 
autologous virus representing a large repertoire of the host’s diverse HIV-1 antigen pool. This 
could elicit primary immune responses specific for each patient’s quasispecies of HIV-1, as well 
as activation of residual HIV-1 specific memory T cells, giving the broadest immune control of 
HIV-1 infection during ART. Such an approach has important public health implications by 
having a strong positive impact on, and improve the control of, HIV-1 infection in persons on 
ART. It also serves as an in vitro priming model for development of prophylactic vaccines 
against HIV-1 and other infectious agents.  
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II.    CHAPTER ONE: INTRODUCTION 
A. HIV: HISTORY AND ORIGIN, DISTRIBUTION, GENOME, EPIDEMIOLOGY, 
TRANSMISSION AND DISEASE PROGRESSION 
 
1. HISTORY AND ORIGIN 
For years a new virus silently spread until a glimpse of the future pandemic appeared in 
1979-1981 when rare types of pneumonia, cancers (e.g. Kaposi’s Sarcoma), and other illnesses 
were being reported by doctors in Los Angeles, New York and San Francisco [1]. These patterns 
of illness were seen predominantly among the homosexual male population and stood out, since 
individuals with seemingly healthy immune systems, succumbing to these types of conditions 
was unusual. It was not until 1983 that scientists discovered the virus, first named human T-cell 
lymphotropic virus-type III / lymphadenopathy-associated virus (HTLV-III/LAV) and later 
changed to human immunodeficiency virus (HIV) [2,3]. For many years scientists theorized as to 
the origins of HIV and how it appeared in the human population, most believing that HIV 
originated in other primates and was introduced into the human population when hunters became 
exposed to their infected blood. Recently, molecular phylogeny studies revealed that the  
predominant strain of HIV-1 in the developed world originated in a subspecies of chimpanzees 
(Pan troglodytes troglodytes) [4-6], and HIV-2 originated in SIVsm of sooty mangabeys 
(Cercocebus atys) [4,7,8]. 
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2.  DISTRIBUTION 
HIV is classified as a member of the lentivirus genus of the Retroviridae family. 
Lentivirus isolates from humans are grouped into one of two types, HIV-1 and HIV-2, based on 
their genomic sequence and pathogenic potential. These types are unevenly distributed 
throughout the world, HIV-1, the predominant type worldwide, and HIV-2 primarily found in the 
African continent. HIV-1 has been further divided into two subgroups: the M (major) and O 
(outlier) groups. The M group (which is divided into clades A-J) is responsible for the majority 
of infections worldwide whereas the O group is relatively rare and found in Cameroon, Gabon, 
and France [390]. 
 
3.  HIV GENOME 
Infectious virions of HIV contain two identical copies of positive single-stranded RNA, 
about 9.2 kb long. The genomes of all replication competent retroviruses contain three prototypic 
genes (shown in green, Figure 1) flanked by non-coding sequences, termed long terminal repeats 
(LTRs). The first gene is Gag, encoding for structural proteins including the matrix, the capsid, 
and the nucleocapsid. The second gene is Pol, encoding for the viral enzymes reverse 
transcriptase (RT), protease (Pro), integrase (Int). The third gene, Env, encodes the outer 
glycoprotein that mediates viral entry of permissive cell types. Additionally, there are six open 
reading frames (ORF) which are composed of (i) two genes that are essential for HIV replication, 
tat and rev  (shown in red, Figure 1) [9,10], and (ii) four genes of HIV-1, vif, vpr, vpu and nef 
(shown in blue) termed accessory genes because they are non-essential for the viral replication in 
vitro (reviewed in [10]); HIV-2 and SIV differ in an accessory gene, vpx [390]. 
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Figure 1: Genetic organization of lentivirus. The primate lentivirus RNA proteome is 
approximately 9.2 kb in size and encodes structural proteins/viral enzymes which include the 
products of gag, pol, and env genes, which are essential components of the retroviral particle 
shown in green. Regulatory proteins, Tat and Rev, are shown in red and they modulate 
transcriptional and posttranscriptional steps of virus gene expression and are essential for virus 
propagation. The accessory proteins Vif, Vpr, Vpx and Nef are shown in blue and are in general 
not necessary for viral propagation in tissue culture, but they have been conserved in the 
different isolates suggesting that their role in vivo is very important.   
 
 
 
4.  EPIDEMIOLOGY 
The most recent global statistics [391] estimate 38.6 million (33.4-46.0 million) people 
are living with HIV-1 and 4.1 million (3.4-6.2 million) became newly infected with HIV-1 in the 
year.  According to the World Health Organization (WHO), 18.8 million people around the 
world have died of AIDS since the emergence of HIV/AIDS [391].  Focusing specifically in the 
United States, the cumulative estimated number close to 1 million cases (984,155) and the 
estimated number of persons living with AIDS is reported as 433,760 as of 2005 [391]. 
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5.  TRANSMISSION 
Transmission of HIV-1 can occur by several routes: sexual contact (anal, vaginal, or 
oral), by blood or blood products, and from mother to child (in utero, during birth, or through 
breast feeding) [392]. After it was shown that CD4 was the primary receptor, and CCR5 (for 
macrophage tropic) and CXCR4 (for T cell tropic) chemokine receptors were identified as co-
receptors [11-16] for the virus, several thoughts of the initial entry targets for transmission of 
HIV-1 emerged. Some researchers believed that CD4+ T cells [17-19,20], whereas others put 
forth APC (e.g. DC, LC and macrophages) [19,21-23], as the likely target of HIV-1 infection. 
The proposed model of HIV-1 transmission was circumstantially built on a number of studies 
using several culture models [19,23-25] supported by evidence that cell types (macrophages, DC 
and CD4 T cells), expressed the CD4 receptor and CCR5 coreceptor [26,27], their location in the 
mucosa [28] and knowledge of how DC function [29,30]. The proposed sequence of events was 
that HIV-1 sequentially binds to and/or infects DC, which in turn transported virus to T cells 
within secondary lymphnoid organs [31,32] (e.g., the Trojan horse theory). Recently, Hladik et 
al. [33] has come the closest to directly proving this through the use of an explant of human 
vaginal mucosa to demonstrate HIV-1 entry into Langerhans cells (LC) (CD1a+ and MHC II+) 
and CD4+ T cells (both which express CCR5). These cell targets can be strongly (in the case of T 
cells) and partially (in case of LC) blocked when tissues are treated with anti-CCR5 antibodies 
[33].  
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6.  DISEASE PROGRESSION 
Although there is a small percentage of individuals including: (i) high risk commercial 
sex workers (likely repeat exposure to HIV-1 virus) that do not become infected [34-38] (ii) 
infected individuals that do not exhibit evidence of disease progression over extended period of 
time, termed long term non-progressors (LTNP) [39,40], and (iii) ‘elite controllers’ that can 
control virus without any treatment [41-44], the majority of HIV-1 infected individuals follow 
three basic stages of disease progression: (i) primary or acute infection, (ii) asymptomatic 
(chronic) and (iii) AIDS, as illustrated in Figure 2 [45]. 
         
Figure 2: Schematic of typical course of HIV-1 infection showing changes in CD4 and CD8 T 
cell counts in peripheral blood and plasma viral load. Figure from Munier et al., Immunol Cell 
Biol volume 85, 6-15, 2007. Reprinted with permission from Nature Publishing group. 
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Primary infection consists of establishment of a productive infection with HIV-1 in which 
approximately 50% of individuals experience flu-like symptoms (e.g. general malaise, fever, 
lymphoadenopathy) after 3-6 weeks of infection. The persistence and severity of the symptoms 
vary among individuals and are usually spontaneously resolved after about 1 week. These 
symptoms are due to viral replication (reaching levels of 106-107 copies of viral RNA/ml [46] 
and a decline in numbers of peripheral CD4+ T cells [47,48]. The peak of the HIV-1-specific 
CTL response occurs shortly after peak viral load [49,50] and helps control viral replication 
[51,52] resulting in decreases in plasma viral levels (at 3-6 months) that eventually reach a 
steady state [50]. This steady state or viral set point has been shown to represent a strong 
predictor for disease progression [53,54]. Second, following this acute stage, an individual enters 
a phase which is clinically asymptomatic (chronic disease), and can persist for an average of 10 
years in humans [55,392].  During this time although clinically asymptomatic, the delicate 
balance of the host immune system and viral replication dynamics are at constant war. There are 
high cell turnover levels, leading to a persistent state of activation resulting in chronic 
progressive immune dysfunction (reviewed in [45]). During this period, CD4+ T cell counts are 
normally at 600-1,200 cells/mm3, [56] that decrease gradually if infected individuals are left 
untreated.  An untreated individual’s CD4+ T cell counts will eventually drop below 200 
cells/mm3 and reach a level in which the individual becomes susceptible to AIDS-defining 
opportunistic infections [e.g. Pneumocystis carinii pneumonia (PCP)] and neoplasms [45,57,58]. 
This chronic state of progression can be slowed for a majority of individuals when antiretroviral 
therapy (ART) is administered. Effective ART treatment reduces the viral replication rate to a 
degree that is undetectable and partially restores T cells numbers [59-65]. However, it does not 
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eradicate virus, as viral reservoirs remain and lead to progressive infection if ART is 
discontinued.  
 
B.  IMMUNE RESPONSES: THE PLAYERS INVOLVED IN HIV-1 INFECTION 
1.  DENDRITIC CELLS  
Dendritic cells (DC) are present in essentially every tissue, where they operate at the 
interface of innate and adaptive immunity by recognizing pathogens and presenting pathogen-
derived peptides to T cells. Immature DC (iDC) are professional antigen-presentation cells 
(APC) that are positioned throughout the peripheral tissue and act as sentinels against invading 
pathogens [66-69]. Non-specific antigen (Ag) capture is particularly efficient in iDC due to the 
high level of constitutive macropinocytosis. This Ag uptake of DC of exogenous antigen is not 
only in the form of peptides, but in the form of virus-infected, apoptotic, or necrotic cells, 
followed by processing through nonconventional pathways and cross-presentation of antigen in 
the context of MHC class I molecules (MHCI) to CD8+ T cells [70-77].  
In iDC differentiated from blood monocytes, macropinocytosis rates are particularly high, 
such that the cell takes up its own volume in extracellular material every 60 minutes [78]. In 
response to immune stimuli, iDC migrate out of damaged or infected tissue and move to 
secondary lymphoid organs. En route, so-called ‘co-stimulatory’ molecules (e.g. CD80, CD86), 
adhesion molecules [e.g. CD50, CD54 (ICAMs)] and signaling molecules such as CD40, are 
upregulated or appear on the DC surface. DC are activated in response to engagement of toll-like 
receptors (TLR) by natural adjuvants such as bacterial cell wall components [79,80] or by 
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ligation of CD40 by CD40L expressed by activated CD4 helper T cells [81]. As indicated above, 
one consequence of activation is increased DC expression of T cell costimulatory ligands. In 
particular, increased CD80 and CD86 expression levels, above the basal resting state level, are 
critical for DC induction of CD8+ T cell activation. In fact, there is some evidence that it may not 
always be necessary [82] or sufficient [83,84] to prevent tolerance. Upon arrival in the lymphoid 
organs, DCs are partially matured, a process that is completed upon subsequent interaction with 
T cells. At this stage, endocytosis has ceased to be of primary importance to DC function and is 
virtually shut down. 
DC activation stimulates T cells to produce a variety of cytokines which play a central 
role in Th1/Th2 paradigm. Basically, Th1 cells are considered IFNγ-producing effector cells that 
can activate cytotoxic T cells. Th2 lymphocytes secrete IL-4, which induce humoral immune 
responses dominated by enhanced IgE production such as in allergic diseases. Thus, it is 
imperative for immunotherapies of HIV-1 infection to induce Th1 cell activity, with resultant 
enhancement of antiviral CTL activity. 
 
2.  CD8+ T CELLS 
It is known that CD8+ T cells recognize peptides of 8-11 amino acids presented within 
the binding cleft of MHCI molecules. Most cells present peptides derived only from endogenous 
proteins on MHCI molecules and, by doing so, become targets of the efferent effector function of 
CD8+ T cells. Recognition of infected cells is mediated by interaction of the TCR on the CTL 
with pathogen derived peptides in the context of MHCI molecules. All nucleated cells, (except 
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neurons), express MHCI molecules, which allows CTL to CD8+ T cells to respond. It is these 
responses that appear to play an important role in viral control. CTL responses are present during 
primary infection and the onset of this activity correlates in time with peak viral load during 
primary infection. Depletion of these cells in SIV-infected macaques results in increased viral 
load and more rapid disease progression [51,52,85]. Many of these characteristics are found in 
CD8+ T cells isolated from patients with chronic HIV-1 infection. In contrast to HIV-1-specific 
cells in patients with naturally controlled infection, CD8+ T cells from those with chronic 
progressive infection proliferate poorly in response to cognate antigen, are poor producers of IL-
2 and TNF and have an effector rather than central memory phenotype [86,87]. Further studies 
have suggested a halt in maturational development of these cells with defective expression of 
CD127 [88-90] and an accumulation of immature effector cells that have apparent deficiencies of 
effector molecules (granzyme B, perforin) production, increased levels of markers of senescence 
or terminal differentiation such as CD57 [91] and reduced expression of co-stimulatory 
molecules such as CD28 and CD27 [92-95]. Flow cytometry has revolutionized the HIV field by 
allowing researchers, for the first time, the capability of looking at rare events and many cell 
surface markers at once (11-color, 13 parameters). This has been especially powerful in the 
definition of CD8+ and CD4+ T cells and their classification as naïve, effector, central memory, 
or effector memory [86,94,95]. The considerable efforts to delineate and characterize the subsets 
of antigen-specific memory T cells including cell surface markers including CD45RA/RO, 
CD27, CD28, CD57, CD62L, CD127 and CCR7 have all been used in various combinations to 
define memory cell populations that are responsible for effective antiviral immunity [86,94,96-
99]. This information can be combined with the functional correlates (IFNγ, TNFα, IL-2, 
CD107a and b, perforin, granzyme A and B) which have been termed ‘functional signatures’ 
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[87,100]. Understanding these functional patterns of antigen-specific responses is likely to lead 
researchers to the crucial missing pieces of viral control in acute and chronic infections. 
 
3.  CD4 + T CELL HELP 
CD4+ T cell epitopes are processed by APC in membrane-bound vesicles, where the 
native proteins are degraded by proteases into the peptide fragments that bind to MHC class II 
proteins. They are then delivered to the cell surface, where class II-peptide complexes can be 
recognized by the CD4+ T cells [101].  The importance of CD4+T cell was appreciated for 
another reason, i.e., their help of maintenance of CD8+ T cell functions during chronic infections 
[102,103]. Many chronic infections are more severe in the absence of adequate CD4+ T cell help, 
and the quality of the CD8+ T cell response is often substantially worse. Elimination of CD4+ T 
cells also leads to the impaired long-term control of murine gammaherpes virus infection 
[102,104,105]. For humans, loss of CD4+ T cells during HIV-1 infection often precedes or is 
associated with CD8+ T cell dysfunction and AIDS progression [106].   CD4+ T cells also appear 
to play an important role in the optimal priming of CD8+ T cells during acute infections [107-
109].  
The common finding of these recent reports is that secondary expansion of memory 
CD8+ T cells following re-stimulation is dramatically reduced if the CD8+ T cells were originally 
primed in the absence of CD4+ T cells [110].  Studies using acute infections of mice suggest that, 
as long as CD4+ T cells were present during the initial priming, then CD4+ T cell help was 
dispensable during secondary challenge. However, recent studies with chimpanzees have 
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demonstrated that optimal recall CD8+ T cells responses following hepatitis C virus (HCV) 
infection can depend on the presence of CD4+ T cells at the time of HCV challenge, even when 
the virus-specific CD8+ T cells were originally primed in the presence of CD4+ T cell help [111].  
CD4+ T cell responses (provide CD40 signaling to host APC) are likely important for optimal 
generation of memory CD8+ T cells following acute infections and for sustained CD8+ T cell 
responses during chronic infections. However, HCV experiments suggest that CD4+ T cell help 
may also be critical at the time of challenge with virulent infections. Recently, a new facet to DC 
communication with CD4+ T cells was shown, where they increase the ability of DC to attract 
and retain Ag-specific CD8+ T cells [112]. Together, these studies provide evidence that in the 
absence of signals provided by CD4+ T cells, the differentiation program of CD8+ T cells may be 
altered. It will be important to determine the impact of CD4+ T cell deficiency on not only the 
generation of functional effector CD8+ T cells, but also on memory CD8+ T cell differentiation, 
including the transition from T cell central memory to T cell effector memory [103]. 
 
4.  CYTOKINE INFLUENCES ON CD8+ T CELLS: IL-7 AND IL-15 
During CD8 T cell response to infection, there are three characteristic phases: a period of 
initial activation and expansion, a contraction or death phase, and the establishment and 
maintenance of memory [132-134]. The analysis of CD8+ T cell responses has been greatly 
facilitated by the introduction of MHC tetramer technology that allows accurate enumeration and 
phenotypic characterization of antigen-specific T cells by flow cytometry [135,136]. IL-15 
reduces spontaneous and CD95/Fas-induced apoptosis of HIV-1-specific CD8+ T effector 
memory populations [119]. An important component of this homeostatic turnover is that there is 
no net increase in CD8+ T cell numbers, resulting in maintenance of the memory CD8+ T cell 
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pool at a constant size. The cytokines IL-7 and IL-15 are primarily responsible for this 
homeostatic turnover of memory CD8+ T cells [137-141]. In particular, in the absence of IL-15 
signal, memory CD8+ T cells can be generated, but these cells fail to undergo homeostatic 
division and their cell numbers decline over time [137]. In comparison, IL-7 signals provided 
during the memory phase of the immune response appear more important for memory CD8+ T 
cell survival [138,142].  
IL-15 has been reported to have effects on T cell survival and proliferation [113-121], 
both in vitro [122-124] and in vivo [122,125-128]. This cytokine shares overlapping biologic 
properties with IL-2, acting through the β and γ chains of IL-2 receptor [129,130], as well as, 
through a specific IL-15 receptor α chain. It is thought to possibly mediate anti-apoptotic signals  
(i.e. Mcl-1 and Bcl-2) [122,131].  
Current research by Melchionda [115] has shown that adjuvant  IL-7 or IL-15, overcomes 
immunodominance and improves survival of the CD8+ T cell memory pool. Vaccines that aim to 
induce and maintain high level T cell responses for chronic infections such as HIV and cancer 
have had limited success. The challenges of immunization for cancer and chronic infections (e.g. 
HIV-1, HCV) are multifaceted and include ongoing mutation of target antigens [143], anergy 
and/or suppression due to chronic antigen overload [144], and the large size of the target pool, 
which requires dramatic T cell population expansion for therapeutic benefit [145]. Thus, new 
approaches for increasing in the size and broadening the diversity of effector and memory pools 
generated after immunization are needed to improve the prospect of generating an effective 
preventative vaccine for HIV-1 and to enhance the effectiveness of immunotherapy for chronic 
infections. Currently, paradigms hold that memory CD8+ T cells represent highly “fit” cells 
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derived from the surviving effector T cell population, thus leading to the prediction that therapies 
which augment T cell effector pools will also augment T cell memory pools. 
 
C. IMMUNE ESCAPE: GENETIC FACTORS (VIRAL AND HOST) 
1.  VIRUS HETEROGENEITY 
Today we know that due to the infidelity of reverse transcription (RT), HIV-1 rapidly 
diversifies in the infected individual and, as a consequence, is able to adapt readily to changes in 
its environment. A possible underlying mechanism for the loss of anti-HIV-1 CTL is 
development of immunologic escape mutants of HIV-1. Env gp120, and particularly the V1-V5 
domains, demonstrates a great deal of heterogeneity during the chronic phase of infection 
[146,147]. This heterogeneity is due to the infidelity of the RT [148]. Several error mechanisms 
have been ascribed to viral polymerases [149]. First, direct mis-incorporation of a non-
complementary nucleotide produces a single-base substitution error. Second, slippage of the two 
DNA strands may occur at repetitive sequences to generate either a deletion (unpaired 
nucleotide(s)) in the template strand or addition (unpaired nucleotide(s) in the primer strand); 
each of these events can include one or more nucleotides. Third, frame shifts are caused by 
misincorporations followed by misalignment of the template-primer. Fourth, base substitutions 
can also result from dislocation mutagenesis, which adheres to the following pathway: slippage, 
correct incorporation, and realignment.  Each of these mechanisms can yield single-nucleotide 
mutations over large distances to produce changes involving many nucleotides. 
The infidelity of RT for a variety of retroviruses has been determined in vitro by 
measuring misincorporation in reactions with defined RNA or DNA templates. This 
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misincorporation rate for HIV-1 RT ranges from 1 per 1,700 to 4,000 nucleotides [150,151] 
whereas, other retroviruses have lower rates (e.g., error rates are 1 per 9,000 to 17,000 
nucleotides for avian myeloblastosis virus and 1 per 30,000 nucleotides for murine leukemia 
virus). Retroviral polymerases do not have 3’-5’ exonuclease proofreading activity for correcting 
polymerization errors. Therefore, these enzymes as a group have a much higher misincorporation 
rate than cellular DNA polymerases. The HIV-1 genome is about 9.2 kb with an in vivo error rate 
that is estimated to be about 1 to 3 misincorporations per replication cycle [149]. 
Through the error mechanisms stated above, as well as recombination events, RT is 
responsible for the production of viral sequence diversity in infected individuals. HIV-1 infection 
differs from many other acute and chronic viral infections in the magnitude and duration of 
viremia, as well as, the high level of genetic variation in vivo [152]. This rapid turnover 
generates 109 to 1010 virions per day [153,154], which accompanied by a high degree of 
misincorporation, leads to the generation of a broad range of quasispecies with a heterogeneous 
pattern of immunogenicity. 
2.  GENETIC POLYMORPHISMS AND DISEASE PROGRESSION 
A number of host genetic factors influence the rate of disease progression in HIV-1 
infection. The most extensively studied of genetic factors that might affect disease progression 
are associations between HLA alleles and disease progression not only for HIV-1 but for other 
pathogens as well. Over many years, it has become clear that host genetic differences between 
individuals, as well as between species affect the susceptibility or resistance of disease 
progression. These differences reveal a clinical spectrum of rapid, intermediate, or slow 
progression or, more rarely, nonprogression to AIDS within infected populations. A range of 
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distinct genetic host factors, linked to the relative susceptibility or resistance to AIDS, influences 
disease progression.  
The human leukocyte antigens (HLA) loci encode two distinct major MHCI  and MHCII, 
haplotypes of highly polymorphic cell surface glycoproteins that bind and present processed 
antigenic peptides to T cells of [155,156]. MHCI molecules present endogenous antigen, 
synthesized and processed in the infected cells, to the CD8+ cytotoxic T lymphocytes (CTL) that 
kill the infected cell.  Class II MHC molecules present peptides as well, but is generated in the 
intracellular vesicles of B cells, macrophages, and other cells to be recognized by CD4+ T cells. 
The highly polymorphic HLA class I molecule helps to determine the specificity and 
repertoire of the immune response. The extensive polymorphism at the HLA loci is thought to 
have arisen through natural selection by infectious diseases, operating on the diversity generated 
by mutation, gene conversion and recombination [157,158]. At a population level, genetic 
diversity of the HLA loci is maintained by enhanced antigenic peptide-binding capacity, and 
therefore resistance to infectious disease. Individuals heterozygous at HLA loci are capable of 
presenting a broader array of pathogen-derived peptides, resulting in a more diverse CTL 
repertoire and the ability to resist a greater breadth of infectious pathogens; whereas individuals 
that are homozygous at HLA loci have been observed as having a more severe disease 
progression. The MHC alleles that are most consistently reported in the literature of having 
associations on the impact of HIV-1 disease are: HLA-B27, B57, B58 [44,159-167] 
nonprogression and, HLA-A1, B8 [168,169], and HLA-B35 rapid progression [170,171]. HLA 
associations with HIV-1 disease have been somewhat inconsistent [393] depending on the size 
and population sample studied.   
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In 2004 instead of looking at a single MHC class I haplotype for disease association, 
Kiepiela et al., [172] took a more general approach and demonstrated the relative contributions 
of HLA-A and -B alleles in their inferred impact on disease progression. In studying this cohort 
(375 HIV-1 infected individuals) it was demonstrated that a 2.5 fold increase in the number 
CD8+ T cell responses were found to HLA-B compared to HLA-A.  Futhermore, a greater 
selection pressure (4.4 fold) is imposed on HIV-1 by HLA-B than HLA-A alleles. 
Recently, Fellay et al. [173] used a whole-genome association strategy to try to explain 
the variations seen among HIV-1 infected individuals. This study looked only at the early phase 
(characterized by asymptomatic viral set-point) of 30,000 individuals by combining 4 studies in 
which the authors identified 486 individuals matching their criteria. All the samples were 
genotyped with Illumina’s HumanHap550 Beadchip with 555,352 single-nucleotide 
polymorphisms (SNPs). The first association was found in HCP5 (HLA complex P5) which 
contributed 9.6% of total variation of set point. The authors showed HCP5 and ZNRD1 (zinc 
ribbon domain-containing 1) contribute to the control of associated HLA-B*5701 (a known 
association with nonprogression). The second was found in a region of HLA-C (rs9264942) 
lowered viral load. A third set of polymorphisms was located in a gene upstream that encodes for 
RNA polymerase I subunit with also contributed to the total variation in disease progression. 
This important work identified two new mechanisms that were not previously associated with 
disease progression: HLA-C and RNA polymerase subunit. These new associations give 
possibilities for new targets in therapeutic interventions. 
Other genetic factors affect virus entry and critical processes for the intracellular 
replication of lentivirions as well as subsequent early innate and highly specific, adaptive host 
responses [174]. Greater than ten genes and fourteen alleles with polymorphisms in the 
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chemokines or their receptors have been associated with either a positive or negative effect on 
infection and disease progression. The most notable, of the chemokine receptors, CCR5 is 
associated with the resistance to HIV-1 infection [175] by a 32bp deletion--the others include 
CCR2, CXCR4, CXCL12, CX3CR1 and Rantes (CCL5) (reviewed [176]). Transporter-
associations with antigen-presenting (TAP) genes, which are members of the MHC class III 
family of alleles, also has been observed to play a role in determining the rate of disease 
progression in HIV-1 infection putatively by their ability of transport efficiency of processed 
antigen from proteasomal cleavage [177, 178-182].  
 
3.  CONSEQUENCES OF HIV-1 GENETIC VARIATION 
Sequence variation is thought to affect CTL recognition in at least three ways: (1) 
blocking correct transport and processing of the antigen, (2) blocking peptide binding to the 
MHC molecule, and (3) blocking optimal recognition of the peptide MHC complex by the TCR. 
In the last mechanism, either the peptide/MHC complex will fail to engage the TCR [183], or the 
TCR may be sub-optimally engaged by the altered peptide/MHC complex, resulting in a 
decreased ability of that CTL to respond upon encountering a cell that presents that 
peptide/MHC complex to which the CTL was originally generated (antagonism) [184,185]. The 
earliest study demonstrating virus escape from a CTL response was in a LCMV model in which 
mice transgenic for an LCMV specific T cell reported TCR derived from a T cell clone were 
infected with a high dose of LCMV, and mutant viruses were rapidly selected [186].  
Studies have shown that CTL are directed across the proteome and each protein can have 
multiple T cell epitopes [187,188,189]. In studies reported by Couillin et al. [190], individuals 
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infected with HIV-1 generated a great diversity of CTL.  This study looked at the 
immunodominant region in the Nef protein and suggested that in vivo escape from CTL epitopes 
occurs as a result of alterations in anchor residues (affecting peptide binding to MHC), non-
anchor residues (affecting TCR recognition) and flanking residues (affecting 
transport/processing).  
Borrow et al [191] demonstrated that CTL escape in primary infection on the single 
epitope level from a HLA-B44 positive subject. The epitope from the CTL clone contained the 
HLA-B44 binding motif. As disease progressed, the emergence of a mutant virus population was 
able to escape recognition by the primary HIV-1 specific CTL response. Goulder et al [192] 
subsequently showed immune evasion for HLA-B27 restricted epitope at stages of high viral 
replication and turn over. Other studies that included siblings with identical HLA types studied 
gag by restricted HLA-B8 epitope and were able to demonstrate genetic variation in gag altered 
CTL recognition.  
Brumme et al. [193] analyzed 765 HIV-1 infected individuals that were drug naïve and 
demonstrated that MHCI–mediated responses within selected functional, accessory and 
regulatory genes did not target anchor residues for CTL escape within published epitopes. They 
found an inverse relationship between HLA mutation within these published epitopes and lower 
CD4+ T cell counts, supporting the link between disease progression and the presence of escape 
mutations. Many other studies [194-198] looking at HIV-1 escape CTL epitopes across the 
genome, support this mechanism as one major contribution to the virus’ ability to avoid 
replication control. 
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The simian model also supports that CTL escape mutations are associated to disease 
progression [199-202]. As example, SIV-infected macaques were followed from primary 
infection to death [203]. Ten CTL epitopes accumulated amino acid replacements and showed 
evidence of positive selection by the time the macaques died. Many of the amino acid 
replacements in these epitopes reduced or eliminated MHCI binding and/or CTL recognition.  
Interestingly, emerging data suggest that HIV-1 and SIV have adapted to their animal 
hosts since their introduction into these species, and are likely to continue eliminating important 
targets of the host cellular immune responses (CTL) [193,194,204,205]. However, in 
interpretating these studies, one must be cognizant of founder effects which could be responsible 
for the observation of imprinting (e.g. escape mutations that are selected due to population 
frequencies of common MHCI alleles) and perpetuate in the population. The escape mutations 
that can perpetuate in the circulating viral population are capable of frequent reversion of escape 
CTL epitopes in hosts that do not express the particular allele.  These CTL epitopes restricted by 
common alleles may be eliminated from the circulating viral population, (termed ‘relic’ epitopes) 
and should be considered in epitope vaccine designs. 
For my research, however, having documented that variants of HIV-1 that escape a 
defined CTL response do exist within patients, it becomes logical to ask if these variants then 
predominate within the viral quasispecies of the patients. Viruses with variant amino acid 
sequences in CTL epitopes would have a survival advantage if these sequences escape 
recognition by the majority of CTL prevalent at the time. The persistence over time of escape 
mutant sequences that has been documented is strong evidence for this argument. If an epitope 
region must be conserved to ensure viral replication or survival, such antigens might elicit 
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sustained CTL responses. If, on the other hand, the virus tolerates amino acid changes in a CTL 
epitope, then escape mutants might arise. With the help of the Los Alamos Database [393], 
which compiles sequence differences between various HIV-1 clades and the sequence variability 
among defined optimal epitopes, we have the capacity to look at autologous virus isolates and 
CTL epitope changes over disease progression for many subjects.  
 
D. VACCINES AND IMMUNOTHERAPY 
The global need for an effective vaccine against HIV-1 is an understatement; growing 
numbers of individuals living with AIDS is reaching an astounding number. In some countries in 
Africa the infected individuals that succumb to AIDS leave many orphaned children and the 
instability of these nations could be leading to unknown levels of economic strife, leaving 
communities in crisis.  
It has been over 200 years since Edward Jenner’s first experimental vaccination—that is, 
inoculation with the related cow-pox virus to build immunity against smallpox. The history of 
vaccine development has been largely successful (i.e. influenza, measles, HBV, diphtheria, etc.) 
however, their development has outpaced our understanding of what surrogate markers correlate 
with protection. 
Over the past decade, major improvements in our understanding of memory T cell 
generation and differentiation have prompted the design of sophisticated vaccine strategies that 
induce potent and long-term antigen-specific cellular immunity. In addition to the design, the 
route of administration, the dose, the timing of the prime/boost regimens, and the processing and 
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presentation of the immunogens all influence the type and quality of immunity induced by the 
candidate vaccine.  
Many HIV-1 vaccine efforts have emphasized breadth of MHCI restricted CD8+ CTLs 
due to previous studies showing a strong correlation with lower viral load. However, the current 
knowledge of the factors determining HIV-1-specific CTL antiviral efficacy is inadequate to 
interpret fully their significance when detected. One report provides evidence that broad CD8+ 
specificity may not be the answer for vaccination strategies. Kiepiela [206] compared influences 
of the number of epitopes targeted with HIV-1 proteins (Gag, Pol, Env, and 
accessory/regulatory) on viral load. The researchers revealed only Gag responses correlated with 
lower viral loads. Specifically, targeting zero or 1 Gag epitope was not significant, but viral loads 
were significantly lower when > 1 Gag specific CD8+ T cells responses were detected, showing 
an association with disease progression [206]. 
The functional plasticity of the DC and their unprecedented ability to orchestrate the 
immune system makes these cells a desirable candidate for manipulation in a vaccine.  Their 
versatile nature, capacity to process and present various forms of antigen (e.g. whole inactivated 
virus [207-209], live-infected cells [210], apoptotic or necrotic preparations [208] [211], protein 
and peptides [212-214], transfected DC with HIV-1 plasmids of mRNA or DNA [215-218] and 
ex vivo manipulability, all indicate the seemingly limitless means through which DC may be 
integrated into vaccine design.  
The basic rationale for DC immunotherapy in HIV-1 infected persons is to reinstall T cell 
functional responses that resemble those observed in the LTS (long term survivors). How best to 
use DC as a vehicle to overcome immune dysfunction is a difficult challenge. There are many 
obstacles that must be appreciated to achieve the end result—an immune response that controls 
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viral replication. Currently, the primary objective is to elicit strong type-1 immunity; and thus, 
selecting a DC population that engenders such immunity is imperative. There are many cocktails 
of immunomodulating factors that promote DC maturation, each resulting in different immune 
outcomes. When GM-CSF and IL-4 are used to culture monocyte derived (md-DC) for 5 days 
and then compared with IFNγ and GM-CSF (to immunomodulate), the stimulation of naïve and 
memory CD8+T HIV-1-specific responses was superior for the latter. This is most likely because 
IFNα is a type I IFN and has been shown to be essential for effector T cell generation [103]. If 
this group (IFNα and GM-CSF) was compared with IFNγ and CD40L as T cell 
immunomodulators, their IL-12 production levels would have been greatly increased and this 
cytokine contributes prominently to the stimulation capacity of these APC. Current in vitro 
studies ongoing in our laboratory indicate the requirement of CD40L (normally provided by the 
CD4+ T cells) for optimal maturation of DC to produce high levels of IL-12 to elicit a Th1 
response [219]. Unfortunately, since CD40L is not approved for clinical applications, researchers 
have to use pro-inflammatory cytokine (IL-1β, IL-6, TNFα and PGE2) cocktails instead [389]. 
Another problem with ex vivo manipulation of DC for use in immunotherapy is whether 
the cultured cells become functionally exhausted prior to administration by a vaccine in vivo.  
The current standard is to manipulate DC to sustain the production levels of IL-12p70 upon 
subsequent interaction with activated Th1 cells in vivo [220]. PD-1 (programmed death-1) has 
recently been shown to be highly expressed on exhausted T cells during chronic viral infections 
(LCMV, HIV-1 and HCV), and blockade of PD-1 or PD-L1 (programmed death-1 ligand) can 
revive exhausted T cells, enabling them to proliferate and produce effector cytokines [221-227]. 
PD-1L interacts specifically with the B7-1 costimulatory molecules to inhibit T cell responses 
[228]. Therefore, this new parameter should be added to the list of jobs the DC should be able to 
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perform once manipulated ex vivo and re-administered in vivo—that is the stimulation should not 
increase the PD-1 expression levels on CD8+ T cells rendering them ineffective. By artfully 
priming DC to enhance Th1 over Th2 responses, the deficiency in T cell reactivity during HIV-1 
infection could potentially be reversed and immunologic normalcy restored. 
Although we remain ignorant of how some individuals are able to control virus 
replication, LTS (long term survivors) immune response profiles provide researchers a 
population of individuals in which to study and thereby an opportunity to understand the possible 
parameters that equate with long term protection [18,229]. As we become more knowledgeable 
of efficacious CD8+ T cell responses, and what roles they provide in protection; we will be able 
to develop detection methods as surrogate markers that correlate to protection in evaluating de 
novo vaccination strategies. 
 
E. METHODS: PREDICTION OF CTL EPITOPES AND PRIMING MODEL 
 
1.  COMPUTER PREDICTION OF CTL EPITOPES: 
Several computer algorithms have been devised to take advantage of protein sequence 
information to search for T cell epitopes. A number of CTL epitopes have been predicted for 
other viruses using this method, including herpes simplex virus (HSV), and HCV. These 
algorithms test each sub-sequence of a given protein for traits thought to be common to 
immunogenic peptides, thus locating regions with a higher-than-average likelihood of inducing a 
cellular immune response in vitro. Using these algorithms, the array of sites that would require in 
vitro testing for immunogenicity may be significantly reduced, directing experimental efforts to 
more promising segments of the protein and thus dramatically reducing the time and effort 
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needed to locate T cell epitopes. We chose to use such a computer algorithms (BIMAS) 
(http://thr.cit.nih.gov/molbio/hla_bind) [230-233] in order to scan the vast amount of available 
autologous viral sequences for each of the patients over the course of their disease progression. 
This program method was developed by Parker et al. [230] and is based on coefficient tables 
deduced from the published literature. For HLA-A2, peptide binding data were combined 
together to generate a table containing 180 coefficients (20 amino acids x 9 positions), each of 
which represents the contribution of one particular amino acid residue at a specified position 
within the peptide [230]. This website allows users to locate and rank 8-, 9-, or 10-mer peptides 
that contain peptide-binding motifs for HLA class I molecules and has been updated over the 
years from the literature. This program is one that has been shown to be accurate in its predictive 
value for the haplotypes HLA-A*0201 and B*0702 when compared to other systems [234]. The 
published literature includes binding motifs for a wide variety of human class I and class II MHC 
alleles.  
However, it remains for the most part unclear whether such motifs hold true predictive 
value. Only a small fraction of the possible peptides that can be generated from proteins of 
pathogenic organisms actually generate an immune response. In order to be presented to CD8+ T 
cells a precursor peptide must be generated by the proteasome. This peptide may be trimmed at 
the N-terminal by other peptidases in the cytosol.  It must then bind to the transporter associated 
with antigen processing (TAP) in order to be translocated to the endoplasmatic reticulum (ER). 
Only half the peptides presented on the cell surface are immunogenic probably due to the limited 
size of the TCR repertoire. The most selective step is binding to the MHCI molecule, since only 
1/200 binds with an affinity strong enough to generate an immune response [155,231,235-237]. 
For comparison the selectivity of TAP binding is reported to be 1/7 [238]. This all happens in 
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competition with other peptides, so in order for a peptide to be immunogenic, it must go through 
the above described process more efficiently than other peptides produced in a given cell 
(reviewed in [239]). The CTL response against viruses is often focused on a few epitopes, and 
the reason for this selectivity is not obvious. Many peptides were identified in viral proteins by 
scanning for MHCI binding motifs that are able to bind to MHCI molecules [240,241], but this 
does not ensure antigenicity. Therefore, the use of motif-derived epitopes many not represent the 
entire repertoire of peptides from published reports. For this study only two haplotypes: HLA-
A*0201 and –B*0702, were chosen based on their higher frequencies in the Caucasian 
population and extensive evaluation, thereby more acurate availability of prediction data. The 
prediction motifs for these two haplotypes are shown in Figure 3. 
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Figure 3: Motif of HLA-A*0201 and HLA-B*0702. Primary anchor positions and preferred residues are listed 
under the position (Bolded) and the residual or secondary anchor residues are not bold faced.  Motifs are based on 
Falk et al. 1991, Barouch et al. 1995, Englehard et al. 1993 Rammensee et al. 1999 and Brusic et al. 2004. 
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 2.  PRIMING MODEL 
Taking what is known about priming of naïve CD8+ T cells to generate Ag-specific CD8+ 
T cells I developed an in vitro priming model that was originally based upon previous work in 
our lab [211,242] and others [243,244].  Naïve CD8+ T cells egress from the thymus and enter 
peripheral blood and lymphoid organs where they are engaged by MHCI/peptide complex (signal 
1) [245] along with the costimulatory molecules (signal 2) [74,246,247] on the surface of mDC 
activates the T cells to clonally expand and with the help of CD4+ T cells [107-109,248], and IL-
12 (signal 3) (Figure 4) [82,249-253].  
                
Figure 4: Naïve CD8+ T cell require three signals for full activation and avoidance of 
tolerance. Stimulation through the T cell receptor (TCR) and CD28 in the absence of a third 
signal stimulates proliferation, but effector function does not develop and the cells are tolerant 
long term. The third signal can be provided by interleukin-12 or type I interferons produced by 
DCs in response to TLR engagement or CD40-dependent interaction with CD4+ T helper cells. 
Reprinted with permission from Mescher et al. 2006, Immunological Reviews 211: 81-92. 
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The optimal activation of naïve CD8+ T cells requires prolonged exposure to all three signals 
(antigen, costimulatory molecules and IL-12) for 30-60 hours [103,254-256]. However, memory 
CD8+ T cells do not require a third signal to develop effector function [82,251]. All these 
parameters were combined to establish an in vitro priming model that used the high efficiency of 
the APC to process Ag, express high levels of costimulatory molecules (e.g. CD80, CD86) and 
IL-12 production for long periods of time when they encounter CD8+ and CD4+ T cells in culture 
to evaluate immunogenicity against consensus and autologous HIV-1 viral peptides. 
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II. CHAPTER TWO: SPECIFIC AIMS 
My overall hypothesis is that HIV-1 infected subjects with chronic, progressive infection, 
have naïve T cells that can be primed against HIV-1 by antigen loaded DC in vitro, and that this 
can serve as a focus of immunotherapy for HIV-1 infection.  Memory CTL CTL derived in vivo 
from these naïve cells are eventually unable to react to evolving variants of HIV-1, thereby 
allowing escape mutants to replicate and cause disease. The loss of anti-HIV-1 memory CTL 
activity could be due to changes in the CTL epitopes that arise in the variant quasispecies, 
resulting in immune escape. During ART, there is only partial recovery of memory T cell 
immunity to the virus. The effect of progressive HIV-1 infection, and HIV-1 infection after 
ART, on the recovery of the naïve T cell population specific for HIV-1 is not known. This 
presents a major obstacle for development of immunotherapies for HIV-1 infection. To 
overcome this challenge, I further hypothesize that naïve T cells do recover and are able to be 
primed by the persons’s own viral antigens, including immune escape variants, after ART. 
Understanding CD8+ T cell responses in progressive HIV-1 infection and during ART is critical 
to how researchers deal with antigenic diversity of the virus in vaccine design. Many studies 
have examined virus-specific CTL responses, but are still unable to correlate their IFNγ 
production to disease progression, which in part, may be due to the use of consensus strain when 
determining the breadth of responses in different populations. Therefore, the specific aims of this 
project were: 
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Specific Aim 1: Identify potential MHC class I CD8+ T cell epitopes in autologous 
HIV-1 sequences of MACS participant #8.  
A. Identify potential HLA-A*0201 MHC class I CTL epitopes in Gag, Nef and Env of 
HIV-1 autologous sequences of MACS participant #8. 
B. Identify potential HLA-B*0702 MHC class I CTL epitopes epitopes in Gag, Nef and 
Env of HIV-1 autologous sequences of MACS participant #8. 
Hypothesis: The loss of anti-HIV-1 CTL activity during progressive HIV-1 infection could be 
due to changes in the CTL epitopes that arise in the variant quasispecies, specifically in their 
MHC class I binding capacity and its impact on disease progression (e.g., CD4+ T cell counts 
and viral load).   
Methods: Analyze autologous HIV-1 sequences of Gag (p17 and p24), Nef and Env (C2-V5) 
regions from the Multicenter AIDS Cohort Study (MACS) participant #8 to determine potential 
epitopes for binding of peptides to MHCI molecules. The analysis will utilized one of the many 
computer algorithms (BIMAS) that are available to predict potential MHCI binding to regions of 
amino acid sequences.  Based on the analysis of haplotypes HLA-A*0201 and -B*0702, some 9- 
and 10-mer epitopes will be further characterized for functional binding to soluble MHCI 
molecules to access the validity of this model and their impact on disease progression measured 
by associations with the CD4 T cell counts and viral load. 
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Specific Aim 2: Develop an in vitro priming model to evaluate potential binding of 
MHC class I CTL epitopes. 
A. Determine dendritic cell maturation by phenotyping surface expression of CD80, 
CD83, CD86, MHC class I (HLA-ABC), MHC class II (HLA-DR). 
B. Determine mature dendritic cell cytokine production of IL-10 and IL-12. 
C. Determine mature dendritic cells capacity to prime naïve CD8+ T cells. 
Hypothesis: HIV-1 peptide antigen loaded, mature dendritic cells (DC) have the capacity to 
prime naïve CD8+ T cells in vitro. 
Methods: Define the best methods for maturation and antigen presentation of DC for priming of 
T cells through monitoring of their phenotype and cytokine production. Different known DC 
immunomodulation factors will be studied for their capacity to induce primary responses of 
naïve CD8+ T cells in vitro as assessed by chromium release, IFNγ ELISPOT and tetramer 
staining of HIV-1 peptides. 
 
Specific Aim 3: Compare primary and memory response in MACS participant #8. 
A. Determine memory T cell responses to evolving variants over disease progression in 
MACS participant #8. 
B. Determine naïve T cell responses in preseroconversion samples of MACS 
participant #8. 
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Hypothesis: The change in HIV-1 epitopes due to CTL selective pressure will result in failure of 
memory CD8+ T cell responses to late escape variants. However, on ART it is possible to 
enhance secondary and primary T cell responses with DC expressing autologous HIV-1 antigens 
that may potentially help to control viral replication.  
Methods: The new priming model established in specific aim 2 will be used to compare naïve 
CD8+ T cell responses (pre-seroconversion PBMC) to memory (ex vivo PBMC) responses of 
early, late and ART time points during progressive infection of MACS participant #8. This will 
be accomplished by utilizing this individual’s autologous ‘founder’ and evolving viral variant 
sequences over time, and DC derived from his blood monocytes during ART. The 
immunogenicity of these sequences will be assessed by IFNγ ELISPOT assay.  
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Abstract 
 
A hallmark of HIV-1 infection is its high level of genetic divergence over time, leading to 
accumulation of genetically distinct quasispecies within an individual. This genetic diversity of 
HIV-1 can lead to changes in the capacity of viral peptides to bind to MHCI molecules, which in 
turn could result in altered recognition and response by CD8+ T cells. To investigate this effect, I 
identified potential MHCI-binding epitopes of Gag, Nef and Env from evolving viral sequences 
of untreated, HIV-1 infected individuals using an HLA binding prediction model and derived 
peptides from these epitopes. I showed that MHCI epitopes of variants evolving from the 
founder strain have weaker, neutral and stronger patterns of predicted binding. I confirmed these 
patterns using an MHCI binding assay. These changes in MHCI binding could lead to alterations 
in the T cell immune responses and represent a potential viral escape strategy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 33
Introduction 
 
HIV-1, a highly divergent virus, generates genetically variants that are driven by the 
infidelity of the reverse transcriptase (RT).  This high error rate of the RT has been determined in 
vitro [151,257-259] by measuring misincorporations. The genetically distinct variants that are 
generated, leads to an accumulation of variants or quasispecies [260] in the host.  Assessing the 
quasispecies within an individual over time is important for our understanding of impact on 
disease progression and pathogenesis.  However, due to the unusually high level of variants, 
practical approaches dealing with the quasispecies’ impact on disease progression is needed. In 
this study I propose an approach that uses MHC class I (MHCI) epitope prediction modeling and 
their correlations to CD4 T cells and HIV-1 copy numbers as a measure of disease progression. 
MHCI molecules conventionally bind peptides between 8-10 residues, with N- and C-
terminal ends pinned in the binding groove [261]. On average, only 0.1-0.5% of all overlapping 
9-mer and 10-mer peptides spanning a protein will bind to an individual HLA class I molecule 
[262]. Because MHCI binding peptides that bind to different MHCI haplotypes are related by 
sequence similarity, prediction of MHCI peptide binding has traditionally been accomplished 
using sequence motif patterns. These sequence patterns are usually extracted from large numbers 
of known peptides, or from pool sequencing experiments [231,263]. The specific amino acids in 
the motif are anchor residues, which occur at specific positions [263]. Such sequence patterns, 
however, have proven to be over simplifications, as the binding ability of a peptide to a given 
MHC molecule cannot be explained exclusively in terms of the presence or absence of an anchor 
residue [264,265].  
An epitope is defined as the molecular structure recognized by immune receptors, and 
immunogenicity is defined as the capacity of an epitope to induce a cellular immune response. 
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Only peptides interacting with MHC molecules above a certain affinity threshold are likely to be 
recognized by T cells and generate a cellular response [266-268]. Prediction of which peptides 
can bind MHC molecules is commonly used to assist in the identification of T cell epitopes. In 
turn, identification of epitopes is a key step toward accurately measuring immune responses, 
understanding host pathogen interactions, developing diagnostic tools, and the development and 
evaluation of new vaccines. 
Computational prediction and modeling of peptide-MHCI binding is of considerable 
interest because it can greatly facilitate epitope screening, with tremendous concomitant savings 
in time and experimental effort [269].  While some of these methods are structure-based [270-
274] or make use of structural information [275], the majority of binding prediction methods are 
sequence-based, including BIMAS [230], SYFPEITHI [231], RANKPEP [276], SVMHC [277], 
and MULTIPRED [278].  For my analysis of HIV-1 peptide binding to MHCI, I chose BIMAS 
based on the study by Peters et al. [234] who assembled a large database of experimentally 
acquired binding energies with a range of MHC molecules. The authors compared 3,089 9-mer 
and 10-mer peptides binding to HLA-A*0201 to predicted binding scores to measure IC50 [nM] 
(or the disassociation rate) using the BIMAS model, giving an R2 of 0.48 with an area under the 
curve (AUC) of 0.920 and 0.873, respectively, and an AUC=0.908 for HLA-B*0702 9-mers, 
supporting a strong correlation with the predictive power of this model. Therefore, this program 
is one that has been shown to be accurate in its predictive value for the haplotypes HLA-A*0201 
and B*0702 when compared to other systems [234] and was used for the present study. 
Different in vitro techniques are used to verify these in silico predictions, i.e., pMHC-
binding assays using either cell-bound class I molecules (cellular-based assays) or solubilized 
class I molecules (cell-free assays). I have used three of these binding assays to assess the 
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BIMAS prediction model for HIV-1 peptides derived from quasispecies derived from 
Multicenter AIDS Cohort Study subjects with HIV-1 infection. Transporter associated with 
antigen processing (TAP)-deficient T2 cells [279,280] are HLA-A*0201 human cells that are 
defective in antigen processing but effectively present exogenous supplied peptides. Class I 
MHC stabilization assays to estimate peptide binding can be done by incubation of exogenous 
peptide and subsequent cellular staining with a class I MHC conformation dependent antibody 
[281]. A second type of cellular-based assay consists of eluting naturally class I MHC-bound 
peptides from the cell surface of EBV-transformed B cells and of carrying out a competition 
assay with the test peptide and a fluorescence-labeled reference peptide  [282]. A third type of 
binding assay is cell-free quantitative biochemical binding assays to assess the ability of peptides 
to associate with purified class MHCI heavy chain and light chain (β2 microglobulin) in vitro 
[283-286].  Initially, biochemical binding assays used radioactive iodinated peptides in a 
competition setting [287]. More convenient alternatives to radioactive labeling have been 
developed by using fluorescent-labeled peptides [288]. Recently, fluorescence polarization was 
introduced for quantitative affinity measurements [289,290]. The accuracy of affinity 
determination can be indirectly assessed by correlating the measurements from different 
methods. Indeed, Buchli et al. showed a good correlation between relative affinities determined 
by both fluorescence polarization and radioactive methods (R2=0.71-0.86) or between 
fluorescence polarization and peptide elution-based cellular methods (R2=0.62-0.82) [290]. Thus, 
fluorescence polarization-based assays feature high-throughput screening capacity and are 
advantageous over other methods in terms of cost-effectiveness, affinity range, precision and 
reproducibility. 
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In this study, I show that MHCI epitopes of variants evolving from the founder strain 
have weaker, neutral and stronger patterns of predicted binding. I confirmed these patterns using 
a fluorescence polarization-based assay. These changes in MHCI binding could lead to 
alterations in the T cell immune responses and represent a potential viral escape strategy.  
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Materials and Methods: 
Study participant 
Participant #8 is a homosexual male enrolled in the Multicenter AIDS Cohort Study (MACS) 
[291] among a group of individuals for which we had characterized the virologic [292-294] [295] 
and immunologic [296] features. The MACS recruited homosexual/bisexual men in 1983-1984 
and has studied them twice yearly by physical examination and laboratory testing. HIV-1 
seropositivity was defined as a positive enzyme-linked immunosorbent assay (ELISA) and a 
Western blot with bands corresponding to at least two of the Gag, Pol, and Env proteins of HIV-
1. Multiple Gag (p17, p24), Nef and Env (C2-V5) sequences were derived at 6 month intervals 
over the course (greater than 10 years) of infection, with the earliest sequences sampled at 4 
months following seroconversion [294] were used for this analysis. 
 
Analysis of T cell phenotypes 
Lymphocytes are gated on CD45 (PerCP) and then analyzed for CD3+(FITC), CD4+(PE) or 
CD3+(FITC), CD8+(PE) cells were stained according to previously described methods using 
antibodies obtained from Becton Dickinson Immunocytometry Systems (San Jose, CA). 
Unstained cells and isotype-matched, control antibodies were used for accurate discrimination of 
positively staining from negatively staining cells. All analyses were carried out on an EPICS XL 
flow cytometer (Coulter Electronics, Hialeah, FL) and 5000 lymphocytes were analyzed from 
each sample. 
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Measurement of viral load 
Levels of plasma HIV-1 RNA were quantitated by an internal control polymerase chain reaction 
assay [297]. This assay utilizes coreverse transcription and coamplification of the target RNA 
sequence with a control plasmid HIV-1 RNA containing a deletion in the gag region. The assay 
is reproducible and can accurately quantitate 101 to 104 copies of HIV-1 RNA within a linear 
range of amplification, and yields equivalent results on fresh and frozen samples. 
 
Synthetic Peptides 
Overlapping 15-mer peptides spanning the entire Gag, Nef, and Env sequences of HIV-1, each 
overlapped the next by 11 amino acids were analyzed using BIMAS website.  Potential epitopes 
were targeted based on predicted binding scores and previously published as well as trends 
discovered that support CTL loss of reactivity due to evolving variants. Peptides were made at 
ResGen Invitrogen Corporation Huntsville, AL or SynBioSci Corporation Livermore CA. 
 
Peptide binding assay 
The binding of these peptides was examined using soluble HLA-A*0201 and B*0702 to 
determined the IC50 values (Pure Protein, Oklahoma City, OK). Fluorescently labeled control 
peptide and sHLA were incubated with each test peptide until equilibration of peptide 
replacement was reached. Inhibitory concentration (IC50) values were calculated using a dose-
response curve. A fluorescently labeled control peptide and soluble HLA were incubated with 
each peptide until equilibration of peptide replacement was reached as read on an Analyst AD 
plate reader (Molecular Devices, Sunnyvale, CA). Fifty-percent inhibitory concentration (IC50) 
was calculated by using a dose-response curve. The log10 IC50 for the peptides used in this study 
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were compared to those of a panel of reference viral peptides with known binding capacity in 
order to define their relative binding affinities [298,299]. The fluorescence polarization binding 
affinity categories were divided based on these cut-offs: high binding affinity < 3.7, medium < 
4.7, low < 5.5, and non-binding < 6.0 (calculated to the artifical log IC50). 
 
Statistical Analysis  
Statistical correlations were determined with a nonparametric Pearson’s correlation coefficient 
and significance (P values) using the standard Student T-Test through SigmaPlot 9.0 software. 
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 Results  
MACS participant #8 was selected for this study due to availability of autologous 
sequences and T lymphocytes data for more than 10 years (Figure 5) and having common 
haplotypes HLA-A*0201 and HLA-B*0702.  
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Figure 5: HIV-1 infected participant. T lymphocyte counts and HIV-1 copies over disease 
progression. Absolute T cell counts over the course of follow-up, CD3 (black diamond), CD4 
(green square), CD8 (yellow triangle), and RNA copies (red square) are shown for MACS 
participant #8. 
 
This analysis was conducted using predictions matrices from the website 
(http://thr.cit.nih.gov/molbio/hla_bind) that has a free, open-access computer algorithm called 
BIMAS [231,233,276] through the Los Alamos HIV Database [293]. This prediction model was 
recently shown to be accurate in its predictive value for the haplotypes chosen for this study 
[234]. The published literature includes binding motifs for a wide variety of human class I and II 
MHC alleles, however it remains for the most part unclear whether such motifs hold true 
predictive value for immunogenicity.    
 41
 I first identified the ‘founder’ strain of participant #8 for two common haplotypes in the 
Caucasian population, HLA-A*0201 and HLA-B*0702, including 9- and -10mer analysis to 
determine the initial number of potentially immunogenic or targeted CTL epitopes spanning the 
HIV-1 genome (Figure 6A, 6B reveal Gag p17 and Gag p24 respectively, Figure 6C Nef and 
Figure 6D Env (C2-V5) regions).  
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Figure 6. Predicted binding of founder strain of HIV-1. 
Predicted binding of MACS participant #8 autologous founder strain spanning Gag, Nef, Env. 
Predicted binding scores are shown for 9-mer A*0201 (blue), 10-mer (green), 9-mer A*0702 
(red) 10-mer (black). 
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While the preponderance of epitopes identified, were present in the Gag (p17 and p24) regions 
(57%), Nef and Env (C2-V5) did not reveal a significant difference, 21% and 22% respectively. 
Interestingly, Kiepiela et al. [206] demonstrated that the number of epitopes targeted against Gag 
were associated with viral control. Although, if you look at the immunologic from a previously 
published from our lab [296] for this individual, the CTL responses against Gag drop-off 
precipitously by the second year (Figure 21 page 93).  Although many predicted binding epitopes 
are identified within this region, and therefore would suggest that this individual would control 
virus, this was not seen. Identification, in itself, of potential epitopes from this region, does not 
necessarily translate into CD8+ T cell response, determining the IFNγ responses (ELISPOT) to 
these epitopes, along with their variants, would need to be ascertained in order address this 
critical issue. 
I then wanted to determine if there were any differences in the number of potential CTL 
epitopes identified by HLA alleles (A*0201 or B*0702) because it has been shown that a 2.5 
fold increase in the number of CD8+ T cell responses was found to HLA-B when compared to 
HLA-A [172]. I did not find any significant difference among predicted epitopes by haplotype 
(HLA-A*0201 = 48%, B*0702 = 52%) or 9-mers versus 10-mers (51%, 49% respectively) of the 
total potential epitopes identified.  
Once the initial epitopes were identified within the founder strain, the task became which 
potential CD8+ CTL epitopes contributed to this individual’s disease progression. To observe 
this, I analyzed autologous viral sequences over the course of infection pre- and post-drug visits. 
A representative analysis of HLA-A*0201 9-mer predicted binding scores is shown in Figure 7 
demonstrating evolutionary changes spanning the genome.  
 44
Gag-p17         Gag-p24                     Env C2-V5                             Nef
Yrs 
post 
SC
0.33
1.16
1.66
2.08
2.50
3.08
3.50
4.00
4.58
5.08
5.58
6.00
6.33
6.83
7.92
8.42
8.75
9.50
10.50
5-10
10-15
15-20
20-30
30-35
35-50
>=50
1     2 4 83                             5   6                                7      9
** * * * ***
Viral evolutionary changes in HLA-A*0201 predicted binding scores of 9mers: 
subject #8 (HLA-A2, A24, B7, B40)
* **
* = published epitope in Los Alamos Database
 
Figure 7: Scanning the impact of viral evolutionary changes on HLA-binding. 
Predicted binding to HLA-A*0201 9mers across the genome over years following seroconversion, was 
mapped for sequences (Gag-p17, Gag-p24, Env, Nef) in subject #8. Each 9-mer amino acid motif in the 
sequence alignment was colored according to predicted HLA-binding score indicated in the score key. 
Each protein analyzed revealed a trend of three patterns: (i) increasing (shown in blue: #’s 1, 3, 5, 6, 7, 
9), (ii) decreasing (shown in red: #’s 2, 4, 8) (iii) constant. CTL epitopes that are denoted with an 
asterisk (*) at the top are HLA-A*0201 epitopes published in the Los Alamos database. 
 
Predicted binding to HLA-A*0201 9-mers across the genome, over ~10 years following 
seroconversion, was mapped for sequences [Gag-p17, Gag-p24, Env (C2-V5), and Nef] in this 
individual. Each 9-mer amino acid motif in the sequence alignment was colored according to 
predicted HLA-binding scores indicated in the key. Epitopes that show a pattern of decreasing 
binding score over time is indicated by red colored numbers at the top (epitopes # 2, 4, 8).  
Initially, I hypothesized that if a decrease in the predicted binding score of a CTL epitope was 
determined, this would indicate a decrease in the peptide to bind to the MHCI groove to be 
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presented for recognition by the TCR for immune recognition and hence effect disease 
progression due to the lack of viral replication control.  
Through this analysis, however, I found a large number of predicted epitopes that 
demonstrated a trend to increase the predicted HLA-binding score over time (depicted in blue, 
epitope #s 1, 3, 5, 6, 7, 9). I then considered the possibility that the accumulation of epitopes 
demonstrating increasing predicted binding scores could potentially be attributed to a viral 
escape mechanism. The summation of stronger binding affinities of CTL epitopes that do not 
efficiently control viral replication in vivo could be associated with disease progression. This 
illustration represents analysis of HLA-A*0201 9-mers only and the same analysis was repeated 
for HLA-A*0201 10-mers and HLA-B*0702 9- and 10-mers (supplemental data in Appendix A-
C).  Scatter plots of each clone were plotted over years post seroconversion, as well as, the 
average predicted binding score (of the clones) for each visit to determine if a correlation existed 
with time. If the correlation value was R2 > 0.5, the epitope was further analyzed for an 
association with disease progression via the CD4, CD8 lymphocyte counts and viral load 
corresponding to that visit. A representative for each of the three trends identified (decreasing, 
increasing and neutral) is shown in Figure 8 (top row) and correlated with lymphocyte and viral 
RNA levels (middle row) and then corrected for ART initiation (bottom row) where I did not 
include visits after the initiation of ART that would have an impact on the immune selective 
pressure of the viral mutation of epitopes. 
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Figure 8  Representative predicted MHC class I  binding score trends. 
The average predicted MHCI binding scores for each visit post seroconversion of participant #8 
are depicted in the top row with correlations of the three examples of binding patterns: 
decreasing, increasing and neutral. Correlations of lymphocytes and HIV copies versus the 
average predicted binding scores over the course of infection (middle panels), or corrected for 
ART (bottom panels) in which visits when on drug are excluded. 
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 Both Gag epitopes displayed, reveal a strong correlation R2 > 0.8 which is further associated with 
CD4 counts (R2 > 0.7) as compared to a known CTL epitope SL9(p17 77-85LAI) (SLFNTVATL) 
which did not reveal any associations with the average predicted binding scores over disease 
progression (R2 = 0.0673), CD4 T cell counts (R2 = 0.0042) or viral RNA levels (R2 = 0.0035) 
when corrected for ART treatment. All epitopes with decreasing or increasing trends are listed in 
Table 1. 
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Table 1  Summary of MHC class I epitope binding predictions pre drug 
Decreasing Trend Scatter plot Avg binding Avg bind/CD4 Avg bind/CD8 Avg bind/RNA Avg bind/CD4 Avg bind/CD8 Avg bind/RNA
Protein Haplotype Sequence Length R2 value R2 value pvalue R2 value pvalue R2 value pvalue R2 value pvalue R2 value pvalue R2 value pvalue R2 value pvalue
Gag A*0201 ALQTGSEEL 9mer 0.5577 0.8774 4.904E-06 0.8545 4.9E-06 0.1413 2.47E-12 0.1139 0.00125 0.7181 1.12E-06 0.1216 1.8E-08 0.2866 0.0009
Gag B*0702 GCRQILEQL 9mer 0.0226 0.2688 2.753E-11 0.162 1.45E-05 0.0077 5.69E-12 0.1983 0.00128 0.1461 2.59E-06 0.2997 3.35E-08 0.1818 0.001
Gag A*0201 NLQGQMVHQA 10mer 0.5622 0.4887 0.4028001 0.2274 4.24E-06 0.377 2.21E-12 0.0632 0.00125 0.1756 9.77E-07 0.391 1.62E-08 0.1754 0.0009
Gag A*0201 AEWDRLHPV 9mer 0.0154 0.0072 4.241E-14 0.0434 0.000163 0.4815 4.05E-11 0.7801 0.00133 0.0073 1.52E-05 0.6046 1.26E-07 0.8466 0.001
Nef A*0201 LTFGWCFKL 9mer 0.5013 0.4066 0.0202811 0.1603 1.26E-06 0.6453 2.58E-09 0.1381 0.04793 0.1359 9.9E-08 0.6326 5.43E-08 0.2079 0.048
  Nef  A*0201 LTFGWCFKLV 10mer 0.5358 0.4268 0.0118598 0.1797 1.27E-06 0.6415 2.6E-09 0.1383 0.04793 0.1544 1E-07 0.6281 5.48E-08 0.2124 0.048
  Nef  B*0702 SPKRQEILDL 10mer 0.0442 0.1628 0.0675555 0.0684 5.1E-05 0.1232 9.29E-08 0.0207 0.04844 0.0146 1.15E-05 0.1012 1.39E-06 0.0494 0.0485
  Nef  B*0702 TPGPTRYPL 9mer 0.0411 0.0085 3.705E-09 0.0211 5.25E-05 0.0226 3.59E-08 0.4392 0.04878 0.5837 3.8E-06 0.2048 5.86E-07 0.7037 0.0488
Env A*0201 NIGPGRAFYA 10mer 0.4108 0.5021 0.9928496 0.2725 7.05E-07 0.4001 7.28E-14 0.07 0.01279 0.2208 1.7E-07 0.4472 2.47E-09 0.1965 0.0147
Env A*0201 NTLEQVVKKL 10mer 0.006 0.0499 0.0461108 0.0639 1.19E-06 0.0468 1.05E-13 0.0376 0.01283 0.0345 2.62E-07 0.0548 3.21E-09 0.083 0.0148
Increasing Trend Scatter plot Avg binding Avg bind/CD4 Avg bind/CD8 Avg bind/CD4 Avg bind/CD8 Avg bind/RNA
2 value pvalue R value pvalue R22
Avg bind/RNA
value pvalue R2 value pvalue R2 value pvalue R2 value pvalue R value R22Protein Haplotype Sequence Length R  value pvalue
Gag A*0201 AINPGLLET 9mer 0.5964 0.8781 0.1394641 0.8649 3.53E-06 0.1235 2.58E-12 0.1373 0.00125 0.7215 4.71E-07 0.098 1.66E-08 0.3593 0.0009
Gag A*0201 KIVRMYSPT 9mer 0.59 0.897 0.0079637 0.8828 6.54E-06 0.1247 4.46E-12 0.1556 0.00127 0.7631 6.23E-07 0.1015 2.05E-08 0.4077 0.0009
Gag A*0201 RMYSPTSIL 9mer 0.4473 0.8999 3.597E-08 0.8331 9.1E-06 0.0945 5.36E-12 0.1633 0.00127 0.6544 9.1E-07 0.0367 2.7E-08 0.1167 0.001
Gag B*0702 SNPDCKTIL 9mer 0.507 0.8418 0.1247798 0.8368 3.35E-06 0.0362 2.47E-12 0.2928 0.00125 0.7082 4.7E-07 0.0002 1.66E-08 0.1008 0.0009
Gag B*0702 ASRELERFAI 10mer 0.5936 0.8748 0.0034392 0.856 0.000161 0.1414 1.24E-10 0.1153 0.00132 0.7223 5.73E-06 0.1232 6.87E-08 0.3463 0.001
Nef A*0201 RQEILDWI 9mer 0.1965 0.7325 0.0112086 0.375 1.99E-06 0.5431 3.88E-09 0.0939 0.0386 0.1074 1.45E-07 0.6474 7.25E-08 0.3603 0.0396
Nef B*0702 GALDSHFL 9mer 0.4821 0.365 3.301E-07 0.1893 2.77E-06 0.5552 4.82E-09 0.1076 0.03868 0.1834 2.11E-07 0.5443 9.36E-08 0.1535 0.0397
Nef B*0702 LVYSPKRQEI 10mer 0.3736 0.2934 0.0304435 0.3309 1.52E-06 0.3492 3.19E-09 0.1383 0.03855 0.5102 1.24E-07 0.3456 6.56E-08 0.2383 0.0396
Nef A*0201 KLVPVEPGQV 10mer 0.1138 0.6122 4.84E-05 0.494 3.57E-06 0.041 5.85E-09 0.0463 0.03872 0.4089 2.11E-07 0.1197 9.4E-08 0.4888 0.0397
Env A*0201 GQIKCLSNI 9mer 0.2232 0.5703 0.4823079 0.5396 1.88E-07 0.0237 3.22E-15 0.0119 0.01332 0.4964 3.46E-08 0.1305 1.25E-10 0.7922 0.016
Env A*0201 TLEQVVKKL 9mer 0.055 0.2921 0.0831713 0.4228 2.06E-07 0.0704 3.41E-15 0.0139 0.01332 0.6039 3.96E-08 0.1594 1.36E-10 0.2717 0.016
Env B*0702 CVSNITGLL 9mer 0.3888 0.5836 9.233E-07 0.5188 1.71E-06 0.3211 5.13E-15 0.0494 0.0151 0.26 4.8E-07 0.6172 2.9E-10 0.2103 0.0176
Env B*0702 LPCRIKQII 9mer 0.0344 0.0902 0.0002767 0.1879 1.14E-06 0.0795 3.92E-15 0.1261 0.01507 0.1206 3.75E-07 0.1063 2.49E-10 0.0609 0.0176
Env A*0201 QLNESVEINS 10mer 0.0044 0.0057 1.083E-05 0.0022 1.42E-06 0.0505 4.53E-15 0.0442 0.01509 0.018 4.36E-07 0.0819 2.73E-10 0.0847 0.0176
Env A*0201 IIGDIRQAYC 10mer 0.5467 0.7083 3.511E-06 0.5831 2.05E-06 0.5499 5.81E-15 0.0679 0.01512 0.5354 5.31E-07 0.6966 3.1E-10 0.2688 0.0176
Env A*0201  AMYAPPISGL 10mer 0.1222 0.0057 1.083E-05 0.002 1.18E-06 0.0513 5.74E-15 0.0227 0.00823 0.0179 3.05E-07 0.0827 3.29E-10 0.0527 0.009
Env A*0201 NMWQSVGKAM 10mer 0.0211 0.0753 1.194E-07 0.0728 3.5E-06 0.1878 1.19E-14 0.6002 0.00828 0.0007 8.32E-07 0.2116 6.1E-10 0.667 0.009
Env B*0702  CVSNITGLLL 10mer 0.4548 0.653 2.488E-06 0.415 1.41E-06 0.4592 6.43E-15 0.1006 0.00824 0.3403 3.29E-07 0.5799 3.45E-10 0.3269 0.009
Env B*0702  AMYAPPIRGQ 10mer 0.2252 0.4977 0.1060592 0.456 1.29E-07 0.0115 3.56E-15 0.0929 0.00732 0.3336 2.06E-08 0.0808 1.38E-10 8.00E-18 0.0084
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Based on the analysis of eliminating epitopes by R2>0.5 correlations, 17 epitopes listed in Table 
2 have predicted binding affinities that potentially could be attributing to disease progression. 
Due to the nature of uncertainty of a predicted value derived from a computer algorithm, I 
analyzed all the epitopes to see if any associations were neglected by allowing the initial criteria 
of predicted binding versus time at R2 > 0.5 as a cut-off value, which added five epitopes (Table 
2 in red) which could be contributing to disease progression based on CD4 and viral load 
associations.  
I next selected some known MHCI epitopes to be accessed for binding affinity analysis as 
determined by fluorescence polarization [288] which is more convenient than radioactive 
labeling yet retains the same capacity of detection [290].  The strategy was to 
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                                                                                                                                                                                                                                                                                                                                          pre-drug 
Decreasing Trend Scatter plot Avg binding Avg bind/CD4 Avg bind/CD8 Avg bind/RNA Avg bind/CD4 Avg bind/CD8 Avg bind/RNA
Protein Haplotype Sequence Length R2 value R2 value pvalue R2 value pvalue R2 value pvalue R2 value pvalue R2 value pvalue R2 value pvalue R2 value pvalue
Gag A*0201 ALQTGSEEL 9mer 0.5577 0.8774 4.9E-06 0.8545 4.90436E-06 0.1413 2.47E-12 0.1139 0.001253 0.7181 1.12215E-06 0.1216 1.79995E-08 0.2866 0.00094142
Gag A*0201 NLQGQMVHQA 10mer 0.5622 0.4887 0.4028 0.2274 4.23754E-06 0.377 2.20816E-12 0.0632 0.00125 0.1756 9.76654E-07 0.391 1.62411E-08 0.1754 0.00093909
Nef A*0201 LTFGWCFKL 9mer 0.5013 0.4066 0.020281 0.1603 1.25573E-06 0.6453 2.57558E-09 0.1381 0.047928 0.1359 9.8985E-08 0.6326 5.43425E-08 0.2079 0.04801021
  Nef  A*0201 LTFGWCFKLV 10mer 0.5358 0.4268 0.01186 0.1797 1.27342E-06 0.6415 2.60073E-09 0.1383 0.047931 0.1544 1.00291E-07 0.6281 5.4826E-08 0.2124 0.04801343
Env A*0201 NIGPGRAFYA 10mer 0.4108 0.5021 0.99285 0.2725 7.05155E-07 0.4001 7.28279E-14 0.07 0.012792 0.2208 1.70253E-07 0.4472 2.46661E-09 0.1965 0.01473344
Gag A*0201 AEWDRLHPV 9mer 0.0154 0.0072 4.24E-14 0.0434 0.000162888 0.4815 4.05428E-11 0.7801 0.00133 0.0073 1.52057E-05 0.6046 1.25888E-07 0.00098154
  Nef  B*0702 TPGPTRYPL 9mer 0.0411 0.0085 3.7E-09 0.0211 5.25086E-05 0.0226 3.59148E-08 0.4392 0.048784 0.5837 3.79539E-06 0.2048 5.85535E-07 0.04880687
Increasing Trend Scatter plot Avg binding Avg bind/CD4 Avg bind/CD8 Avg bind/RN A
0.8466
0.7037
A Avg bind/CD4 Avg bind/CD8 Avg bind/RN
Protein Haplotype Sequence Length R2 value R2 value pvalue R2 value pvalue R2 value pvalue R2 value pvalue R2 value pvalue R2 value pvalue R2 value pvalue
Gag A*0201 AINPGLLET 9mer 0.5964 0.8781 0.139464 0.8649 3.52905E-06 0.1235 2.58189E-12 0.1373 0.001254 0.7215 4.70672E-07 0.098 1.66346E-08 0.3593 0.00093963
Gag A*0201 KIVRMYSPT 9mer 0.59 0.897 0.007964 0.8828 6.54312E-06 0.1247 4.4576E-12 0.1556 0.001266 0.7631 6.22675E-07 0.1015 2.0498E-08 0.4077 0.00094345
Gag A*0201 RMYSPTSIL 9mer 0.4473 0.8999 3.6E-08 0.8331 9.0993E-06 0.0945 5.35599E-12 0.1633 0.001275 0.6544 9.10258E-07 0.0367 2.69682E-08 0.1167 0.00095007
Gag B*0702 SNPDCKTIL 9mer 0.507 0.8418 0.12478 0.8368 3.35262E-06 0.0362 2.46553E-12 0.2928 0.001253 0.7082 4.70118E-07 0.0002 1.66135E-08 0.1008 0.00093968
Gag B*0702 ASRELERFAI 10mer 0.5936 0.8748 0.003439 0.856 0.000161346 0.1414 1.24307E-10 0.1153 0.001315 0.7223 5.73354E-06 0.1232 6.87024E-08 0.3463 0.00095833
Nef A*0201 RQEILDWI 9mer 0.1965 0.7325 0.011209 0.375 1.98584E-06 0.5431 3.88019E-09 0.0939 0.038598 0.1074 1.4501E-07 0.6474 7.2478E-08 0.3603 0.03963846
Nef A*0201 KLVPVEPGQV 10mer 0.1138 0.6122 4.84E-05 0.494 3.57431E-06 0.041 5.84713E-09 0.0463 0.038723 0.4089 2.10628E-07 0.1197 9.40365E-08 0.4888 0.03973451
Env A*0201 GQIKCLSNI 9mer 0.2232 0.5703 0.482308 0.5396 1.87766E-07 0.0237 3.21804E-15 0.0119 0.013316 0.4964 3.46476E-08 0.1305 1.25259E-10 0.7922 0.0160369
Env B*0702 CVSNITGLL 9mer 0.3888 0.5836 9.23E-07 0.5188 1.71459E-06 0.3211 5.13083E-15 0.0494 0.015103 0.26 4.8047E-07 0.6172 2.9047E-10 0.2103 0.017638
Env A*0201 IIGDIRQAYC 10mer 0.5467 0.7083 3.51E-06 0.5831 2.05303E-06 0.5499 5.80673E-15 0.0679 0.015117 0.5354 5.31463E-07 0.6966 3.09714E-10 0.2688 0.01764657
Env B*0702  CVSNITGLLL 10mer 0.4548 0.653 2.49E-06 0.415 1.40665E-06 0.4592 6.43101E-15 0.1006 0.008242 0.3403 3.29295E-07 0.5799 3.45127E-10 0.3269 0.00896586
Env B*0702  AMYAPPIRGQ 10mer 0.2252 0.4977 0.106059 0.456 1.28875E-07 0.0115 3.55578E-15 0.0929 0.007317 0.3336 2.06111E-08 0.0808 1.37841E-10 8.00E-18 0.00835818
Nef B*0702 LVYSPKRQEI 10mer 0.3736 0.2934 0.030444 0.3309 1.51968E-06 0.3492 3.18953E-09 0.1383 0.038545 0.5102 1.24073E-07 0.3456 6.55583E-08 0.2383 0.03960952
Env A*0201 TLEQVVKKL 9mer 0.055 0.2921 0.083171 0.4228 2.05771E-07 0.0704 3.41002E-15 0.0139 0.013322 0.6039 3.96138E-08 0.1594 1.36029E-10 0.2717 0.01604834
Env A*0201  NMWQSVGKAM 10mer 0.0211 0.0753 1.19E-07 0.0728 3.50343E-06 0.1878 1.18955E-14 0.6002 0.008284 0.0007 8.31904E-07 0.2116 6.09592E-10 0.667 0.00901205
Table 2.  Summary of MHC class I epitope binding predictions
 
Summary of MHC class I epitope binding.
List of all the HLA-A*0201 and B*0702 predicted 9- and 10-mer CD8+ T cell epitopes for Gag, Nef and Env that revealed R2 > 0.5 for increasing or 
decreasing trend over time.
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choose known HLA-A*0201 (Table 3) and HLA-B*0702 (Table 4) epitopes and evolving 
variants that displayed a diverse range of predicted binding scores spanning the viral genome to 
determine if predicted scores that had low scores could be detected in this assay.  
 
Peptide sequence Peptide origin Position Sequence ID Peptide length Mol wt. Inhibition % SE Artificial log (IC50) Affinity Category
Gag
1 SLFNTVATL p17 77-85 ABI97965 9 938 92.6 0.6 3.81 Medium
2 SLFNTVAAL p17 77-85 ABC94954 9 965 91.9 0.8 3.84 Medium
3 SLFNTVATP p17 77-85 AAK31062 9 935 31.4 1.1 5.24 Low
4 SLFSTVATL p17 67-75 CAB00235 9 981 94.5 0.8 3.66 High
5 SLFNTIATL p17 77-85 AAQ73334 9 979 90.6 0.9 3.92 Medium
6 SLYNTVATL p17 77-85 AAQ84410 9 949 91.6 0.8 3.86 Medium
7 PLNAWVKVV p24 16-24 ABI80476 9 999 55.2 1.5 4.81 Low
8 ALNAWVKVV p24 19-27 AAQ10844 9 1029 90.2 0.8 3.93 Medium
9 TLNAWVKVV p24 13-21 CAF74725 9 1002 84.7 0.7 4.16 Medium
10 TLSAWVKVV p24 19-27 BAA93825 9 1030 84.1 0.8 4.18 Medium
11 TLDAWVKVV p24 151-159 AAK66106 9 1025 79.8 1 4.3 Medium
gp120
12 IGPGRAFYAT Env 40-49 AAW67700 10 1022 89.4 0.9 3.96 Medium
13 IGSGRAFYAT Env 83-92 AAY67139 10 1052 8.7 1 5.91 Very Low
14 IGPGRAFYAA Env 83-92 AAY67369 10 1009 15.5 0.9 5.64 Very Low
15 IGPGRASYAT Env 40-49 CAA87577 10 1124 72.4 0.8 4.48 Medium
16 IGPGIAGYAT Env 43-52 AAF16166 10 992 0 0.6 6.52 No binder
17 IGPERAFYAT Env 43-53 AAF16391 10 1042 8.6 0.7 5.92 Very Low
Nef
18 PLTFGWCFKL Nef 142-151 AAW83599 10 1212 0 1.5 6.35 No Binder
19 PLTLGWCFKL Nef 141-150 ABC94978 10 1214 5.5 1 6.1 No Binder
20 PITFGWCFKL Nef - - 10 1232 1.2 1.6 6.35 No Binder
21 PVTFGWCFKL Nef 136-145 CAA13504 10 1200 0 1.5 6.48 No Binder
22 PLCFGWCFKL Nef 136-146 ABF47497 10 1212 52.4 1.2 4.86 Low
23 PVCFGWCFKL Nef 136-147 ABI15291 10 1177 23.7 1.8 5.41 Low
24 PLCFGWCFKP Nef 126-135 AAD17151 10 1200 26.5 0.4 5.34 Low
25 PMCFGWCFKL Nef 134-142 ABC94970 10 1198 28.3 1.7 5.3 Low
26 VLVWRFDSSL Nef 222-231 ABG91352 10 1221 75.9 1.4 4.4 Medium
27 VLVWKFDSSL Nef 181-190 ABG90487 10 1193 77.4 1.2 4.37 Medium
28 VLVWKSDSSL Nef 185-194 AAW80944 10 1235 58 1.7 4.76 Low
29 VLVWKFDSNL Nef 183-192 AAG44220 10 1263 79.4 0.8 4.31 Medium
30 VLVWKFDSKL Nef - - 10 1220 54.6 5 4.82 Medium
31 VLVWKFDSHL Nef - - 10 1133 82.9 1 4.22 Medium
32 VLVWKFDSRL Nef 181-190 ABI81102 10 1243 74.3 1.4 4.44 Medium
33 AFHHVAREK Nef 194-202 BAF31431 9 1094 0.0 1.4 6.60 No binder
34 AFHHVAKEK Nef 191-199 ABD78408 9 1066 0.0 1.5 6.65 No binder
35 AFHHVAREM Nef 197-205 AAL65487 9 1097 0.0 1.1 6.62 No binder
36 AFRHVAREI Nef 189-197 AAL65487 9 1098 0.0 0.7 6.62 No binder
37 AFHHMAKEK Nef 189-197 CAD23397 9 1098 0.0 1.2 6.64 No binder
38 AFHHVAREI Nef 190-198 AAD31234 9 1079 0.0 1.5 6.53 No binder
39 ASHHVAREK Nef 188-196 ABD78411 9 1034 0.0 1.1 6.54 No binder
40 ALHHVAREK Nef 190-198 AAL65568 9 1060 0.0 0.7 6.66 No binder
41 AFHHMAREM Nef 188-196 AAP74168 9 1129 0.0 1.1 6.62 No binder
42 AFHHLAREK Nef 193-201 AAQ73887 9 1108 0.0 1.8 6.64 No binder
43 AFHHAAREK Nef 188-196 AAZ41643 9 1066 0.0 1.7 6.56 No binder
44 AFHHVAKGK Nef - - 9 994 0.0 1.6 6.51 No binder  
Table 3.  Peptide information and sHLA binding data of HLA-A*0201 epitopes 
 
List of epitopes studied for binding analysis for HLA-A*0201. 
HLA-A*0201 selected epitopes are listed with their binding affinities. The binding motifs of anchor 
residues are in bold within the sequence. 
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 Peptide sequence Peptide origin Position Sequence ID Peptide length Mol wt. Inhibition % SE Artificial log (IC50) Affinity Category
Gag
45 SPRALNAWV p24 145-153 AAZ91801.1 9 1013 87.2 1.2 4.07 Medium
46 SPRTLNAWV p24 146-154 AA047111.2 9 1043 83.9 1.4 4.18 Medium
47 SPRPLNAWV p24 10-18 CAF74725 9 1040 83.9 1.7 4.18 Medium
48 PPRTLNAWV p24 146-154 AAN73737.1 9 1053 82.8 1.5 4.22 Medium
49 SPRTLDAWV p24 148-156 AAK66106.1 9 1044 76.9 1.8 4.38 Medium
50 TPQGLNTML p24 180-188 AAK66135.1 9 974 94 0.9 3.71 Medium
51 TPQDLNTML p24 181-189 ABK63986.1 9 1032 91.1 1 3.89 Medium
52 TPQDLNTVL p24 180-188 AAK66109.1 9 1000 82.9 1.6 4.22 Medium
53 TPQDLSTVL p24 180-188 AAV53316.1 9 1005 80.5 1.9 4.28 Medium
gp120
54 RPNNNTRKSI Env 17-26 ABL61570.1 10 1199 95.6 1.0 3.56 High
55 RPNNNTRKSL Env 17-26 AAR90645.1 10 1199 94.2 1.0 3.69 High
56 RPTNNTRKSI Env 3-12 AAA44380.1 10 1186 93.3 0.8 3.75 Medium
57 RPNNDTRKSI Env 3-12 AAN63831.1 10 1200 91.8 0.7 3.85 Medium
58 RPNNSTRKSI Env 3-12 ABF49652.1 10 1172 91.6 1.3 3.87 Medium
59 RPNNNTRRSI Env 3-12 ABJ09741.1 10 1227 89.1 1.1 3.99 Medium
60 RPNNNTRKST Env 3-12 AAC04009.1 10 1187 87.8 1.3 4.04 Medium
61 RPSNNTRKRI Env 15-24 CAA10604.1 10 1241 84.3 1.5 4.17 Medium
62 RPNNNTRKRI Env 3-12 ABK33582.1 10 1268 79.3 1.8 4.32 Medium
63 RSNNNTRKSI Env 24-33 AAC97418.1 10 1189 78.6 1.5 4.33 Medium
64 RPNNNTGKRI Env 3-12 AAC04032.1 10 1169 77.4 1.8 4.36 Medium
65 RPNNNTRKCI Env 14-23 AAY17456.1 10 1215 65.2 2.0 4.63 Medium
Nef
66 FPIRPQVPL Nef 68-76 ABF30477.1 9 1066 95.0 1.0 3.62 High
67 FPARPQVPL Nef 68-76 AAL65373.1 9 1024 94.6 0.8 3.66 High
68 SPVRPQVPL Nef 68-76 AAL65364.1 9 1052 94.4 0.7 3.67 High
69 FSVRPQVPL Nef 68-76 AAA44965.1 9 992 53 2.7 4.85 Low
70 FPVRPQVPL Nef - - 9 1042 92.1 1.1 3.83 Medium
71 RPMTCKGAL Nef - - 9 976 93.5 0.8 3.74 Medium
72 RPMTRKAAL Nef - - 9 1043 92.4 1.1 3.82 Medium
73 RPMTWKGAL Nef 75-83 ABF30198.1 9 1059 91.9 0.9 3.85 Medium
74 RPMTWKAAL Nef 80-88 AAG44218.1 9 1073 91.7 1.2 3.86 Medium
75 RPITYKAAL Nef 77-85 AAD31205.1 9 1032 91.4 1.2 3.87 Medium
76 RPMTYKGAL Nef 77-85 ABF30661.2 9 1036 91.1 1.2 3.89 Medium
77 RPMTYKAAL Nef 80-88 ABF30746.1 9 1050 88.0 1.8 4.04 Medium
78 TPGPGIRFPL Nef 128-137 ABF30746.1 10 1054 96.9 0.7 3.4 High
79 TPGPGTRFPL Nef 133-142 ABK6398.1 10 1042 96.5 0.7 3.46 High
80 TPGPGIRYPM Nef - - 10 1088 96.2 0.8 3.5 High
81 TPGPGTRYPL Nef 133-142 AAO47198.2 10 1056 96.1 0.6 3.51 High
82 TPGPGPRYPM Nef - - 10 1072 95.5 1.0 3.57 High
83 TPGPGTRYPL Nef 133-142 AAO47198.2 10 1058 95.5 0.7 3.57 High
84 TPGPGVRYPL Nef 133-142 ABF30533.1 10 1056 94.8 0.9 3.64 High
85 TPGPGPRFPL Nef 133-142 ABF30123.1 10 1038 94.6 1.0 3.66 High
86 TPGPGIRYPV Nef 128-137 AAN03318.1 10 1056 93.5 1.0 3.74 Medium
87 TPGPGPRYPL Nef 133-142 ABF30162.1 10 1054 93.1 0.8 3.77 Medium
88 TPGPGIRFPI Nef - - 10 1054 93 0.9 3.77 Medium
89 TPGPGIRYPL Nef 133-142 ABF30613.1 10 1070 93 1.0 3.78 Medium
90 TPGPGPRYPV Nef - - 10 1040 92.3 1.0 3.82 Medium
91 TSGPGTRFPL Nef 128-137 ABD34935.1 10 1032 52.9 1.6 4.85 Low
92 TKGPGIRFPL Nef - - 10 1085 23.7 1.9 5.41 Low  
 Table 4.  Peptide information and sHLA binding data of HLA-B*0702 epitopes
 
List of epitopes studied for binding analysis for HLA-B*0702. 
HLA-B*0702 selected epitopes are listed with their binding affinities. The binding motifs of 
anchor residues are in bold within the sequence. 
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The binding affinity was determined and is displayed in Figure 9 (and Tables 3 and 4), where the 
log IC50 is plotted versus the predicted binding score. When the binding affinities for the epitopes 
are grouped by protein (Gag, Nef and Env) only Nef demonstrated a strong correlation (R2 = 
0.7948). This strong correlation could be due to the fact that this protein had the greatest number 
of data points and if Gag and Env had more, possibly they would show a strong correlation as 
well. 
            
R2 = 0.0913
R2 = 0.7948
R2 = 0.0767
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
5.5
6
6.5
7
7.5
8
0 25 50 75 100 125 150 175 200
Gag Nef Env
Linear (Gag) Linear (Nef) Linear (Env)
Lo
g 
IC
50
Predicted Binding Score  
Figure 9: Binding affinity by protein (Gag, Nef, and Env). The logIC50 binding affinity was 
plotted against the predicted binding score for each epitope and subdivided by HIV-1 protein 
(Gag, Nef, and Env). Pearson’s product was calculated for each protein. Nef values demonstrate 
association (R2=0.7948). 
 
Taking all the binding affinities together and plotting the percent inhibition versus the predicted 
binding score, there is a low correlation of R2 = 0.275 (Figure 10B).  However, if segregating 
these epitopes by HLA allele, the predictive power for HLA-A*0201 revealed a decent 
association of R2 = 0.6222 (Figure 10A). 
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Figure 10: Binding inhibition by prediction scores of HLA-A*0201 and HLA-B*0702. 
(A) MHC class I binding values for each epitope are grouped by haplotype with an association 
for the HLA-A*0201 epitopes (R2=0.6222), HLA-B*0702 epitopes (R2=0.1537). (B) Combining 
binding inhibition values for each epitope and are not grouped according to haplotype the 
association is only R2=0.275. 
 
Finally, in order to ascertain if this is truly a practical approach to determine epitopes that 
might contribute to disease, I need to further dissect the remaining predicted epitopes and their 
variants functional binding affinities and how accurate the model was at predicting these 
epitopes, and their contribution in disease progression (Table 2). 
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Discussion 
Peptide binding to MHCI molecules is a prerequisite for T cell recognition, but in itself is 
not sufficient for inducing a CD8+ T cell immune response. Some peptides, although considered 
strong binders in biochemical assays, are not properly processed for binding and presentation by 
antigen presenting cells (APC). There are in silico programs that deal with the prediction of 
proteasomal cleavage sites (e.g. PAProc [300]) FRAGPREDICT [301,302] and NetChop [303]) 
and TAP binding patterns (Predict [304]); however these types of analyses were not considered 
in this current study.  
Presently, I focused on identifying potential CTL epitopes and their subsequent binding 
afftinities to MHCI molecules. I used the in silico program BIMAS, which is an interactive 
MHCI binding prediction algorithm, to analyze evolving autologous HIV-1 sequences over the 
course of disease progression for MACS participant #8. This interactive model was able to 
identify three consistent patterns of predictive binding capacity: (i) no change (neutral), (ii) 
decreasing, and (iii) increasing that evolved within the quasispecies. 
The analysis of binding affinities of these peptides to MHCI using the cell line and 
soluble binding assays was deemed too insensitive to reveal differences in binding for our study. 
I therefore, turned to a soluble MHCI binding using fluorescent polarization methods in 
competitive binding analysis of these peptides [290,298] which was determined to have a higher 
throughput potential, as well as, greater sensitivity than our original method (using the TAP 
deficient cell expressing HLA-A2; T2 cells) [279,280] (data not shown).  
Our results for HLA-A*0201 and HLA-B*0702 did show a range from non-binding to a 
strong binding affinity. However, potential epitopes that were determined to have strong 
correlative values (R2>0.5) between predicted MHCI binding and CD4 T cell counts or to viral 
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load need to be further accessed in order to fully appreciate the complete range of scores that 
were identified within the three predictive binding trends of autologous HIV-1 over time in this 
individual. Of a special note, it was interesting that an accumulation of strong associations were 
seen for the predicted binding trend to increase in strength over disease progression. This has 
been noted with other studies [199] and may, in fact, be an escape mechanism where the higher 
binding affinity epitopes are selected for, due to their low disassociation rate and ineffective 
control on viral replication. 
Due to the uncertainty of the predicted binding scores in relation to the actual binding 
affinities, only epitopes with relatively high scores or ones that were previously identified were 
chosen for the current analysis, which mostly from the neutral category of classification. Thus, 
there was no significant relationship between predicted and true binding of HIV-1 peptides to 
MHCI, and disease progression for these chosen epitopes.  Although predicting MHCI binding 
for only the most common HLA variants may provide sufficient population coverage for vaccine 
design, successful prediction for as many HLA variants as possible is necessary to understand 
the immune response in transplantation and immunotherapy. Prediction modeling as an approach 
to evaluating MHCI and II epitopes binding and immunogenicity are desired, in order to reduce 
the high cost and labor intensive nature of such studies. 
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Abstract 
HIV-1 infected persons currently on antiretroviral therapy (ART) still harbor latent viral 
reservoirs that can result in resumption of disease progression.  Human and monkey studies have 
shown correlations of viral control and lack of disease progression with levels of HIV-1 or SIV 
specific cytotoxic T lymphocytes (CTL). Therefore, I propose that a broad and robust primary 
immune response is important for an effective prophylactic or therapeutic vaccine.  In this study, 
I developed an in vitro priming model to show that a primary CD8+ T cell response to HIV-1 can 
be activated in vitro by stimulation of naïve T cells with HIV-1 peptide-loaded dendritic cells 
(DC). The optimal primary T cell response to HIV-1 required maturation of the DC with CD40L 
and interferon (IFN)-γ, and IL-12 and CD4+ T helper cells. The primed CD8+ T cells recognized 
multiple regions of Gag, Env and Nef that corresponded to known and predicted MHCI epitopes. 
This in vitro priming model can be of importance in evaluation of various aspects of HIV-1 
vaccines, including the immunogenicity of predicted and known MHCI restricted epitopes.     
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Introduction 
Initiation of antiretroviral therapy (ART) for the majority of human immunodeficiency 
virus type 1 (HIV-1) infected persons results in a precipitous drop in viral load to undetectable 
levels and a gradual increase in CD4+ T cell numbers [305]. This impressive therapy allows host 
survival, but is ultimately unable to clear the virus from the infected individual. Viral reservoirs 
persist during the course of ART, and only a partial recovery of anti-HIV-1 T cell immunity is 
seen [306-308]. It is believed that CD8+ T cell response are important in host control of HIV-1 
infection and prevention of AIDS (reviewed in [309]), so new strategies enhance anti-HIV-1 
CD8+ T cell immune responses during ART [310-312] are being pursued. One such approach is 
to load antigen (Ag) ex vivo to activated dendritic cells (DC) to present peptides representing 
immunogenic CTL epitopes of HIV-1 [313-316]. These Ag-loaded DC are then re-administered 
to HIV-1 infected persons to stimulate primary and memory anti-HIV-1 CD8+ T cell immune 
responses that could clear the residual viral pools.  
In order to determine potential immunogenicity of regions of HIV-1 to use in 
immunotherapy and potentially for prophylactic vaccine design, I have developed an in vitro 
priming model. Generating and expanding primary immune responses from naïve precursors in 
vitro [71,208,242,243] has been difficult due to the stringent activation and costimulatory 
requirements. Therefore I examined the three major signals required for priming of naïve CD8+ 
T cells, i.e., MHCI/peptide complexes (signal 1) [245], costimulatory molecules (e.g. CD80 and 
CD86) (signal 2) [74,246,247] on the surface of mDC that activates CD8+ T cells with the help of 
CD4+ T cells [108,109,248,317], and IL-12 (signal 3), which induces IFNγ in Th1 cells that in 
turn enhances antigen-specific CD8+ CTL responses [82,103,249-253,255,256,318-321]. The 
results show that DC from HIV-1 negative subjects that were matured with CD40L and IFNγ and 
 60
subsequently loaded with either 9-mer or 15-mer HIV-1 peptides and CD4+ T cells were required 
for efficient generation of antigenically broad and robust, primary CD8+ T cells responses in 
vitro.  
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Materials and Methods 
Dendritic cells (APC) 
To obtain immature DC (iDC), CD14+ monocytes were positively selected from either buffy 
coats (Central Blood Bank, Pittsburgh, PA) or  from peripheral blood mononuclear cells (PBMC) 
using anti-CD14 monoclonal antibody (mAb)-coated magnetic beads (Miltenyi, Auburn CA) to a 
purity of >95%, cultured for 5 days in RPMI-1640 (Gibco, Grand Island NY) supplemented with 
10% FCS (Cellgro) containing 1000U/ml recombinant granulocyte-monocyte colony-stimulation 
factor (GM-CSF) (Amgen, Seattle WA) and 1000U/ml of recombinant human interleukin (hIL)-
4 (R&D Systems) adding fresh cytokines every other day. On the 5th day, the iDC were 
harvested and reset at 1x106/ml and maturation factors were added for 40 hours. Maturation 
reagents included: CD40L (0.5ug/ml Amgen), IFNγ (1000U/ml; R&D Systems) IL-1β 25 ng/ml; 
R&D Systems), IFNα 1000 U/ml; Strathmann Biotech), TNF-α (50ng/ml; BD Biosciences), Poly 
I:C (dsRNA; 20ug/ml, Sigma) for 40 hours to induce DC maturation and immunomodulation. 
 
Synthetic peptides 
Synthetic peptides represent dominant HLA-restricted CTL epitopes for CMVpp65 (495-503) and 
HIV-1 peptides (SL9) SLYNTVATL (p17 77-85LAI), TLNAWVKVV(p24 151-159), KLTSCNTSV(gp120 
192-199), RGPGRAFVTI(gp120 311-320), SLLNATIAV(gp41 818-827) prepared by the Protein Research 
Lab, (University of Illinois, IL) and HIV-1 consensus strain 15-mers overlapping by 11 amino 
acids were provided by the NIH AIDS Research & Reference Reagent Program (Germantown, 
MD)  were used for priming assays. 
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Primary stimulations 
Normal human HLA-A*0201 PBMC or CD8+ T cells were used in primary stimulations. CD8+ T 
cells were enriched through positive selection using CD8 microbeads and LS columns as 
described by the manufacturer (Miltenyi Biotec, Auburn, CA). Primary stimulations containing 
PBMC or CD8+ T cells/well in RPMI 1640 (Gibco) supplemented with 10% fetal calf serum 
(FCS) (Cellgro) with peptide-loaded DC at responder to stimulator (T/DC) ratios of 10:1. Peptide 
loading consisted of two methods: (i) pools of 5 immunodominant epitopes were used for 
establishment of the model and (ii) single peptides were used for tetramer and consensus 
experiments. Antigen loading of the DC was performed by incubation in medium (RPMI-1640) 
without supplemental serum containing 50μg/ml peptide for 2 hours in 370C, 5% CO2 
atmosphere. DC were then harvested and re-suspended with PBMC depleted of monocytes. Co-
cultures were fed with fresh medium supplemented with recombinant IL-15 (2.5ng/ml; 
Peptrotech) and IL-2 (50 U/ml; Chiron, Emeryville CA) after 5 days and thereafter. Secondary 
stimulations (boost) with peptide-loaded DC were added directly to cultures and then harvested 
after 28 days for functional readout assays (Figure 13).  
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Figure 13 In vitro priming model 
Schematic representing DC generation and two rounds of stimulation to naïve T cells and assays 
used as readouts of T cell functions (ELISPOT, chromium release or tetramer staining). 
 
Flow cytometry  
DC Phenotype: Untreated iDC and treated DC were stained with multiple maturation markers 
including CD80, CD83, CD86, MHCI (HLA-ABC), and MHCII (HLA-DR). The DC were 
stained with either phycoerythrin (PE)-conjugated specific mAb (BD Immunocytometry 
Systems, San Jose CA) for CD80, CD83, CD86, and MHCII (HLA-DR) or fluorescein 
isothiocyanate (FITC) for MHCI (HLA-ABC). Appropriate isotype-matched monoclonal 
antibodies (mAb) were used as controls. The DC were assessed by flow cytometry and gated on 
large cells with high side scatter (EPICS XL; Coulter, Fullerton CA).  
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Tetramer staining: To analyze specificity of the presence of antigen-specific CD8+ T cells that 
were stimulated for primary (SL9(p17 77-85LAI)) and memory (CMVpp65 (495-503)) responses after 4 
weeks and 2 rounds of stimulation with DC, cells were harvested and stained with MHC 
Tetramer-Streptavidin-Allophycocyanin (APC) (Immunonomics Beckman Coulter) to either 
Tet+SL9(p17 77-85LAI) , Tet+CMVpp65 (495-503), or Tetneg all APC conjugated and CD8-conjugated to 
APC-PC5. The cells were then read on a flow cytometer (EPICS XL; Coulter, Fullerton CA), 
gating on forward and side scatter for live lymphocytes, and collecting a minimum of 250,000 
gated CD8+ T cells per sample.  
 
DC Cytokine Production (ELISA) 
Supernatants were collected from untreated and 40 hours of treated iDC with different 
maturation reagents: (i) CD40L (0.5μg/ml Amgen), (ii) CD40L + IFNγ (CD40L (0.5μg/ml 
Amgen) (1000U/ml; R&D Systems), (iii) cocktail  (IFNγ (1000U/ml; R&D Systems), IL-1β 
(25ng/ml; R&D Systems), IFNα 1000U/ml; Strathmann Biotech), TNFa (50ng/ml; BD 
Biosciences), Poly I:C (dsRNA; 20ng/ml, Sigma) and assayed for production of IL-12p70, IL-
12p40, IL-2, IL-15, and IL-10 using ELISA kits (R & D) as per manufacture instructions. 
Average of 5 normal donors run in triplicate is reported with + SE. 
 
T Cell Functional Assays 
CTL activity: The cell counts and viability of target cells were monitored by trypan blue dye 
exclusion. The Cr51 labeled target cells were added to the effector cells in triplicate at effector-to-
cell (E:T) ratios (e.g. 40:1, 20:1, 10:1) in 96 well plates. The plates were centrifuged at 50 x g for 
3 minutes and then incubated for 4 hours at 370C under a 5% CO2 atmosphere. Afterward, the 
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radioactivity of the cell-free supernatant was assessed in a gamma counter (Top Count NXT; 
Perkin-Elmer, Shelton, CT). The percentage of lysis was calculated as 100 X (experimental 
counts per minute – spontaneous counts per minute) / (maximum counts per minute – 
spontaneous counts per minute). Specific lysis was expressed as the percentage of lysis in 
peptide-treated targets minus the percentage of lysis in non-peptide-treated targets. 
 
ELISPOT: The 96-well plates (Millipore, MA) were coated overnight at 40C with 5μg/ml anti-
interferon γ (IFNγ) monoclonal antibody (Mabtech, Stockholm, Sweden). The antibody-coated 
plates were washed four times with PBS and blocked with RPMI + 10% FCS for one hour at 
370C. Responder cells were stimulated overnight with peptides (10μg/ml)-loaded DC at a ratio of 
10:1 in 370C, 5% CO2 atmosphere. After development of the spots, the plates were counted with 
an Elispot reader system (Cell Technology, Columbia, MD). Data were expressed as net 
spots/106 cells. The number of spots/106 responder cells stimulated with HIV-1 antigen 
expressing APCs minus number of spots/106 responder cells stimulated with antigen-negative 
APCs. Values greater than two standard deviations of the mean background were considered to 
be a positive response. 
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Results 
Properties of DC required for T cell priming. DC are the critical antigen-presenting cell (APC) 
for inducing primary T cell responses, but they represent a diverse and heterogeneous population 
of cells. Due to the ease of generation, most clinical studies have used monocyte-derive (md)-DC 
cultured in GM-CSF and IL-4 to obtain iDC. To assess the most efficient system for priming of 
CD8+ T cells with mdDC, I first addressed the role of costimulatory molecules, inflammatory 
cytokines, toll-like receptor (TLR) 3 ligand and CD4+ T cells in priming of naïve CD8+ T cells to 
HIV-1. The expression of the cell surface markers were assessed for iDC and DC modulated 
with maturation factors (i) CD40L, (ii) CD40L + IFNγ, and (iii) TLR3-cytokine cocktail. Each 
treatment resulted in significant increases in surface expression of maturation markers CD80, 
CD83, CD86 and MHCI (HLA-ABC) and MHCII (HLA-DR) in percent positive cells (Figure 
11A) and MFI in log scale (Figure 11B).  
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Effect of Immune Modulating Factors on DC Phenotypes
Figure 11: DC phenotype
Different maturation factors were added to iDC for 40 hours and surface expression markers were detected for CD80, 
CD83, CD86, MHC class I ABC, and MHC class II DR was collected and the average of five donors + SE is depicted as 
either (A) percent positive or (B) mean fluorescent intensity (MFI) in log scale.
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Thus, surrogates for activated CD4+ T cells, i.e., CD40L and IFNγ, and a combination of 
inflammatory cytokines and the double stranded RNA TLR3 ligand (polyI:C), were both 
efficient in enhancing expression of DC surface maturation factors (signal 2) that are required for 
stimulation of T cell reactivity. 
The Th1 vs Th2 paradigm is essential in the third signal of CD8+ T cell priming. That is, 
mature DC (mDC) require an additional signal to induce a potent stimuli to produce interleukin 
12 (IL-12) and other cytokines that shift or polarize the immune response directed to Th1 cells 
that in turn lead to induction of CD8+ CTL. The production of Th1 polarizing cytokines by 
untreated or treated DC was therefore determined by ELISA. I found that iDC treated with 
CD40L + IFNγ produced the most IL-12p40 and p70, supporting their potential for priming of 
naïve CD8+ T cells to the greatest extent (Figure 12).  
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Figure 12 DC production of cytokines
Average of five seronegative blood donors are shown for DC cytokine (A) IL-
12p70, (B) IL-12p40, (C) IL-10, (D) IL-2, and (E) IL-15 for each maturation 
group (e.g. iDC, CD40L, CD40L + IFNg, and TLR3-cytokine cocktail).
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Interestingly, iDC treated with the maturation cocktail produced high levels of IL-12, but also 
produced the greatest amount of IL-10, which could down regulate Th1 and CD8 T cell 
responses. IL-2 and IL-15 were not detected.  
 
Priming of CD8+ T cells to HIV-1 peptide loaded DC. I next determined which DC treatment had 
the best capability to prime naïve CD8+ T cells. For this, DC from a HLA-A*0201 HIVneg CMV+ 
subject were loaded with either SL9 (p17 77-85LAI) or CMVpp65 (495-503) immunodominant, HLA-
A*0201 peptides for 2 hours and then added to PBMC for co-culture at a PBMC:DC ratio of 
10:1 for 14 days, followed by a booster (secondary) DC-peptide stimulation. Two weeks after the 
second stimulation, cells were harvested and stained for CD8 and tetramers for SL9 (p17 77-85LAI) 
or CMVpp65 (495-503). Cells were analyzed in a flow cytometer and gated on live lymphocytes 
based on forward and side scatter. A minimum of 250,000 lymphocyte (CD8+ cells) events were 
collected (Figure 14A) and graphically represented in Figure 14B.  
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Figure 14 Maturation DC groups and priming capability
A HLA-A*0201 HIVneg CMV+ donor was used to prime the well documented HLA-A*0201 epitopes SL9 (p17 77-85LAI) and 
CMVpp65 (495-503). Differences in priming and memory expansion can be seen (A) and graphically represented in (B).  
 
The results demonstrate that iDC matured with CD40L + IFNγ were the most efficient at priming 
SL9 (p17 77-85LAI)-specific CD8+T cells, while iDC treated with the maturation cocktail were 
superior for CMVpp65 (495-503)-specific memory T cell expansion. These studies indicate that the 
best maturation treatment for md-DC was CD40L + IFNγ based on the high level of signal 2, i.e., 
co-stimulatory molecules, signal 3 (IL-12) production, and expansion of primary antigen-specific 
responses to SL9 (p17 77-85LAI).  
I then further characterized the functional nature of these primary responses using HLA-
A*0201 normal donors and an array of peptides to determine the killing capacity (51Cr release 
assay) and IFNγ response that could be detected by this in vitro priming system. I treated iDC 
with CD40L + IFNγ, loaded HIV-1 peptides representing known immunodominant epitopes for 2 
hours. I then either co-cultured the mDC with CD8+ T cells or CD8+ and CD4+ T cells, for two 
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rounds of stimulations. Co-cultures were enriched for CD8+ T cells again to equalize the 
responses for comparison.  Superior primary CTL responses were consistently seen in the group 
that contained CD4+ T cells in the chromium release assay (Figure 15A) and by IFNγ ELISPOT 
(Figure 15B), supporting a requirement for CD4+ T cells. T cell responses were detected against 
all five HIV-1 peptides, and were greatest to TLNAWVKVV(p24 151-159) and SLLNATDIAV (gp41 
818-827).  
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Figure 15  CTL activity and IFNg ELISPOT
Comparison of HIV-1 peptide-loaded autologous DC co-cultured with CD8+T cells alone or with CD4+T cells for CTL (A) or IFNγ
ELISPOT (B).  
         
Specificity of primary CD8+ T cell responses for HIV-1.  I next explored the breadth of the 
immunogenicity of DC matured with CD40L + IFNγ, loaded with overlapping 15-mer peptides 
for the Gag, Env and Nef proteins derived from a consensus strain of HIV-1. To validate the 
MHCI prediction algorithm for HLA-A*0201 CTL epitopes, I used predicted binding to MHCI 
molecules of potential 9- and 10-mer HLA-A*0201 CTL epitopes to Gag (Figure 16A), Env 
 71
(Figure 17A) and Nef (Figure 18A) of the consensus strain of HIV-1.  Results are reported as 2 
standard deviations over negative control of priming with DC alone (no peptide). 
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Figure 16  Priming to Consensus Gag
Consensus Gag region of HIV-1 was evaluated for potential CTL epitopes using the algorithm provided by BIMAS (A). Immunogenicity was evaluated by 
antigen-loading DC matured with CD40L + IFNγ for 2 rounds of stimulation, and co-cultured with PBMC for 4 weeks and assayed for IFNγ production in 
an ELISPOT (B). Results are reported as 2 standard deviations over the negative control (primed with DC and no peptide).
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Figure 17 Priming to Consensus Env
Consensus Env region of HIV-1 was evaluated for potential CTL epitopes using the algorithm provided by BIMAS (A). Immunogenicity was evaluated by 
antigen-loading DC matured with CD40L + IFNγ for 2 rounds of stimulation, and co-cultured with PBMC for 4 weeks and assayed for IFNγ production in 
an ELISPOT (B). Results are reported as 2 standard deviations over the negative control (primed with DC and no peptide).
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Figure 18. Priming to Consensus Nef. Consensus Nef region of HIV-1 was evaluated for potential CTL epitopes using the algorithm provided by 
BIMAS (A). Immunogenicity was evaluated by antigen-loading DC matured with CD40L + IFNγ for 2 rounds of stimulation, and co-cultured with PBMC 
for 4 weeks and assayed for IFNγ production in an ELISPOT (B). Results are reported as 2 standard deviations over the negative control (primed with 
DC and no peptide).
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The predicted binding scores for peptide with positive ELISPOT responses within these three 
HIV-1 proteins ranged from 0 to >2000. However, this does not necessarily ensure that the 
predicted epitopes will actually bind to their respective HLA molecules. In fact, only 0.1-0.5% of 
peptides representing a whole protein will bind to an individual HLA class I molecule [262]. 
Therefore, to determine the immune responses to these peptides, the overlapping 15-mers 
spanning the HIV-1 genome were loaded onto mDC (i.e., CD40L + IFNγ) and co-cultured with 
PBMC for two weeks, and boosted with a second stimulation. The cells were tested for 
immunogenicity using the IFNγ response to Gag (Figure 16B), Env (Figure 17B) and Nef 
(Figure 18B) for T cells from two HLA-A*0201 HIV-1 seronegative subjects. Due to the large 
amount of peptides and limited number of cells, I was unable to enrich for CD8+ T cells and 
therefore, was unable to definitively exclude IFNγ production by CD4+ T cells in some of the 
responses. The results show that numerous T cell responses were detected to peptides derived 
from each HIV-1 protein Gag, Env, and Nef. I was able to deduce optimal epitopes from the 
consensus 15-mer overlappings through the use of BIMAS (an in silico MHCI prediction 
algorithm model) and previously published epitopes listed in the Los Alamos HIV Database. For 
Gag (Figure 16B), notably, both HLA-A*0201 matched normal donors were able to mount a 
response to SL9 (p17 77-85LAI) (SLYNTVATL), which supports that these were truly Ag-specific 
CD8+ T cell responses. I have also determined epitopes ranging in predicted binding scores from 
< 50 GLLETSEGC to > 700 YMLKHIVWA, which are both predicted 9-mers of HLA-A*0201, 
as well as 10-mers such as TLQEQIAWMT. Env (Figure 17B) responses revealed a broad and 
robust reactivity encompassing, once again, both 9-mer and 10-mer epitopes. My analysis also 
reveal known epitopes such as ALFYKLDVV (which is also a known HLA-B*0801 epitope) 
detected in the normal donor with this haplotype. Responses to Nef (Figure 18B) also revealed 
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these 9-mer (AAVDLSHFL) and 10-mer (WLEAQEEV) CD8+ T cell reactivities. The two 
donors both targeted all three proteins (Gag, Env, and Nef) comprising of 298 overlapping 
peptides. Overall, 34% (70 corresponding HLA-A*0201 responses) (Figure 19) of the IFN 
positive responses (of 208 positive responses) were concordant (e.g. responses to the same 
epitope) between the two donors. This demonstrates that I am capable of detecting the same 
HLA-A*0201 responses in different donors to a good degree. These data support that my in vitro 
priming model is capable of stimulating naïve CD8+ T cells to a broad array of immunogenetic 
proteins of HIV-1. 
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Figure 19 Summary of primary T cell responses to concensus Gag, Env, Nef 
The two HLA-A*0201 seronegative donors were used to prime naïve CD8+T cells to 15-mers 
overlapping Gag, Env, and Nef  and these IFNγ ELISPOT results were compiled to determine 
the number of CTL epitopes that were targeted by both individuals. 
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Discussion 
Priming of naïve CD8+ T cells has been shown to require three signals, MHCI/peptide 
complex (signal 1) [245] along with the costimulatory molecules (e.g. CD80 and CD86) (signal 
2) [74,246,247] on the surface of mDC which activates CD8+ T cells with the help of CD4+ T 
cells [107-109,248] and IL-12 (signal 3) [82,249,250,252,318,251,253,319-321, 103,255,256]. 
The present study supports these findings, as DC matured with either (i) CD40L, (ii) CD40L 
+IFNγ, or (iii) TLR3-cytokine cocktail all expressed high surface marker levels of co-stimulatory 
ligands, B7.1 (CD80) and B7.2 (CD86) on the DC surface for a strong signal 2 compared to iDC. 
It has been shown that co-stimulation with signal 1 and 2 can elicit several rounds of cell 
division, but effector function and memory require a third signal that can be provided by either 
IL-12 or type I interferons [83,84,322], In the absence of this signal some cells can survive, but 
they are immune tolerant [103]. The importance of IL-12 as a third signal is supported by several 
reports where it augments CTL responses in experimental systems [323,324]. Curtsinger’s group 
used a clever system employing artificial antigen-presenting cells (aAPCs), where microspheres 
expressing MHCI/peptide complex (signal 1) and co-stimulatory molecules (signal 2) were used 
in the presence of IL-12 with naïve or memory cells. The results demonstrated that aAPC were 
able to stimulate cytolytic activity in memory T cells, but were unable to due so in the naïve 
CD8+ T cells unless IL-12 was present [251]. Other studies have shown that clonal expansion 
(using carboxyfluorescein-diacetate-succinamidyl-ester (CSFE) dye labeling) can occur, but 
effector functions are not developed [84,253].  Collectively, this information led us to determine 
the cytokine profile of the various DC maturation groups in which iDC treated with CD40L + 
IFNγ produced the most IL-12p40 and p70.   
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Secondly, I verified that increased levels of Th2 type cytokines (IL-10) were not present, 
and thus should not skew our desired Th1 priming responses. Indeed, using DC matured with 
CD40L+IFNγ resulted in priming of CD8+ SL9(p17 77-85LAI) Tet+cells. Based on this 3 signal 
priming model, I then demonstrated the capability of DC treated with CD40L + IFNγ to induce a 
broad spectrum of primary CD8+ T cell responses to five immunodominant HLA-A*0201-
restricted epitopes. As expected based on the well known helper effects of CD4+ T cells,  I found 
that CD4+ T cells were required for efficient priming of HIV-1 specific CD8+ T cells. The 
primed CD8+ T cells exhibited HIV-1 peptide-specific cytolytic activity and IFN production 
that was optimized by the presence of autologous CD4+ T cells. I postulate that the CD4+ T cells 
provided the necessary IL-2 signals when a secondary stimulation is given [325]. 
I then used this model and naïve CD8+ T cells from two HIV-1neg HLA-A*0201 donors 
in the presence of CD4+ T cells with CD40L + IFNγ mDC for in vitro priming to consensus 
sequences of overlapping 15-mers to Gag, Env and Nef regions of HIV-1. I found that the 
primed CD8+ T cells from both donors exhibited a broad immunogenicity (IFNγ production) for 
many well documented epitopes in an ELISPOT as a surrogate of function. Using a stringent 
cutoff for a positive response, many T cell responses were detected which encompassed HLA-
A*0201 9- and 10-mers of HIV-1 known to be epitopes from published reports compiled by the 
Los Alamos HIV Database [393], as well as unknown, possible epitopes. Moreover, the number 
of potential T cell epitopes that matched between the two donors was 34%. Using BIMAS 
prediction modeling with the Los Alamos HIV Database we identified many potential MHCI 
binding epitopes for Gag, Env and Nef among the peptide regions that were positive for T cell 
reactivity in our priming system.  
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Presently, I cannot rule out the possibility that some of these responses are from CD4+ T 
cells due to the fact that we were unable to enrich CD8+ T cells for each of these responses. 
However, there are many known CTL epitopes within the 15-mers previously detected in 
functional assays by other groups [393], and predicted in BIMAS by us, thus supporting that the 
responses are CD8+ T cell specific. Confirmation that these are indeed CD8+ T cell epitopes, 
however, requires that they be mapped to their minimal, 9- and 10-mer MHCI epitopes. 
Notably, this is the first study to demonstrate that in vitro priming of CD8+ T cells to a 
large library of HIV-1 peptides elicits a broad spectrum of epitope specificities. Because the 
control of HIV-1 replication is largely dependent on CD8+ T lymphocyte responses specific for 
immunodominant viral epitopes, vaccine strategies that increase the breadth of dominant epitope-
specific responses by such potent priming effects should contribute to containing HIV-1 spread. 
However, developing immunotherapy strategies for clinical use to elicit a broad spectrum of 
CTL responses will require a further understanding of the mechanisms responsible for 
immunodominance [326].  My data show, nevertheless, that it is feasible to engineer DC to 
enhance the primary responses of naïve CD8+ T cells to a broad array of HIV-1 epitopes while 
on ART. This form of immunotherapy could ultimately improve control of viral replication and 
disease. Moreover, this in vitro T cell priming model makes it possible to evaluate potential 
epitopes of many different pathogens and their immunogenicity for vaccine application. 
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Preface  
This manuscript is in preparation. James Mullins, Joseph Margolick, Homayoon Farzadegan, and 
Raj Shankarappa contributed the autologous virus sequence data for this study. Xiao-Li Huang 
established and conducted the memory T cell ELISPOT assays.  
Bonnie Colleton selected and had commercially synthesized all the autologous peptide sequences 
used in the T cell memory and priming assays, applied her in vitro T cell priming model 
developed in aim 2. She also conducted all of the T cell priming experiments, setup and helped 
oversee the memory T cell assays (including the extensive decisions on the choice of HIV-1 
peptides to use for each time point, given the low numbers of PBMC available), and analyzed, 
interpreted, and organized for presentation all of the memory and primary T cell results. 
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Abstract 
Loss of CD8+ T cell reactivity to constantly evolving variants of HIV-1 is associated with 
progression of HIV-1 infection, termed immune escape.  I examined whether immune escape of 
HIV-1 is related to the inability of HIV-1 variants to prime naive CD8+ T cells to become 
memory T cells capable of responding to these variants. CD8+ T cells obtained from an HLA 
A*0201 B*0702 HIV-1 infected subject >1 yr before seroconversion (HIV-1 plasma RNA and 
antibody negative) were primed with autologous dendritic cells (DC) loaded HIV-1 Gag, Env 
and Nef peptides derived from autologous HIV-1 sequences over several years after 
seroconversion to HIV-1. Primary T cell responses (IFNγ ELISPOT) before seroconversion in 
the MACS subject were compared to memory T cell responses detected during his 15 years of 
infection, before and after virus-suppressive antiretroviral therapy (ART). The results showed 
that a robust, broad spectrum, primary CD8+ T cell response was induced by peptide-loaded DC. 
This included primary T cell reactivity to autologous HIV-1 variants that exhibited immune 
escape, i.e., failed to activate memory T cell responses several years after seroconversion and 
during ART. These results show for the first time that a robust, multi-epitope, primary CD8+ T 
cell response can be induced to autologous HIV-1 strains, including immune escape variants in 
vitro. This study indicates that the human host has the necessary repertoire of naive CD8+ T cells 
to respond to HIV-1 variants in vitro, even though memory T cell reactivity is lost over time to 
these HIV-1 epitope sequences during progressive infection. This supports use of HIV-1 
prophylactic and immunotherapeutic vaccines that target DC to prime broad T cell reactivity. 
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Introduction 
The prognosis of HIV-1 infected persons has dramatically improved since the discovery 
of combination antiretroviral therapy (ART). Although latently infected reservoirs remain in 
treated individuals, ART has unquestionably been beneficial in reducing HIV-1-associated 
morbidity and mortality. HIV-1 replication can cause direct cytopathic effects on T cells, as well 
as disturb the relative contributions of T cell homeostasis and induce apoptosis in subpopulations 
of T cells. Successful management of HIV-1 disease depends largely on the degree of durability 
of viral load suppression and on the ability to preserve and restore immune function [60,327-
336]. The use of ART is associated with varying degrees of immune reconstitution, especially 
concerning HIV-1-specific immune responses [337] [338].  
While recovery of CD4+ T cells in HIV-1 infection during ART has been attributed to the 
production of naïve T cells, and has been associated with the thymus size in children [339,340] 
and adults [341-348], the recovery of naïve CD8+ CD45RA+ CD62L+  [335,336] T cells remains 
unclear. It has been suggested that naïve CD8+ T cells survive without dividing, while memory 
CD8+ T cells survive by proliferating upon antigen (Ag) recognition [123, 349]. The presence of 
phenotypically naïve T cells in athymic mice and humans suggests that extra-thymic pathways of 
T cell development exist [350-354]. The bone marrow, liver, intestines, mesenteric lymph nodes 
and peripheral lymphoid organs [355-358] have all been proposed to provide the signals required 
for T cell maturation. The level of CD8+ T cells that readily undergo apoptosis in HIV-1 infected 
persons has been suggested as a predictor of immune restoration [359,360] whereas others 
[361,362] have determined that the activation levels are independent of viral load and CD4 cell 
counts. This variability in the literature reflects the different thresholds and T cell markers of 
subpopulations used in the studies, as well as the time ART was initiated during disease 
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progression. Indeed, it has been shown that some immunodeficient patients experience increases 
in immune restoration on ART, regardless of factors such as persistent viral replication [363], 
age [364], cytokines [365,366] and hormones [367]. 
I believe that the recovery of naïve CD8+ T cells during ART is critical to restoration of 
immune control of HIV-1 infection. These naïve CD8+ T cells would serve as precursors for 
new, central memory and effector memory CD8+ T cells that, if engineered by a potent 
immunotherapy, could control viral infection together with ART.  Furthermore, these CD8+ T 
cells should have a large magnitude and breadth of responses directed against all HIV-1 proteins 
as in natural HIV-1 and SIV infection [164,368-372]. However, T cell immunity to HIV-1 during 
natural infection also shows a clustering of responses to conserved regions of the virus [368-
371,381]. Moreover, several studies have failed to demonstrate that anti-HIV-1 CD8 T cell 
responses correlate with viral load or CD4 T cell counts [368-372].  I believe that the clustering 
of responses to the conserved regions of HIV-1 could be explained by these studies using 
overlapping peptides based on consensus HIV-1 strains, and not taking into account the high 
divergence of HIV-1.  I further hypothesized that use of autologous virus, especially for the Env 
protein, as an immunogen will reveal dominant epitopes that were previously missed.  
Our research group has recently administered ex vivo, consensus strain HIV-1 antigen 
(Ag)-loaded dendritic cells (DC) in a phase I clinical trial to HIV-1 infected persons to enhance 
anti-HIV-1-specific CTL to further control viral replication during ART [389]. In the present 
study, I have addressed whether such DC-based immunotherapies have the capacity to prime 
HIV-1 specific CD8+ T cells. Naïve CD8+ T cell lack unique markers for purification, moreover 
memory T cells respond and replicate vigorously to antigen in vitro, quickly outcompeting naïve 
T cells.  Therefore I chose not to attempt purifying naïve CD8+ T cells from persons on ART for 
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use in my priming assays. Instead, I exploited the rare capacity of the Multicenter AIDS Cohort 
Study (MACS) [291] to access participants for which we had previously characterized the 
virologic [292,294,306] and immunologic [296] features, to evaluate primary CD8+ T cells 
responses to autologous HIV-1 from cryopreserved PBMC obtained pre-seroconversion. These 
HIV-1 negative samples were stimulated in an in vitro priming model (Colleton unpublished) to 
autologous viral sequences of a MACS participant for comparison to his memory T cell 
responses after infection, and to an HIV-1 seronegative donor matched at HLA-A*0201 and 
HLA-B*0702 haplotypes for a comparison of primary CD8+ T cell responses. I demonstrate a 
robust, broad spectrum of primary CD8+ T cell responses that were induced by DC loaded with 
peptides based on the subject’s ‘founder’ strain and late variants that exhibited immune escape. 
While the extent of natural immune restoration to autologous HIV-1 antigens on ART remains 
unresolved, my data suggest that T cell reactivity that has been lost over the course of disease 
progression can be at least partially recovered during ART by priming with DC loaded with late 
epitope variants. 
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Materials and Methods 
Study participants 
MACS participant #8 is a homosexual male enrolled in the Multicenter AIDS Cohort Study 
(MACS) [291] among a group of individuals for which had been characterized virologically 
[292,294,295] and immunologically [296]. The MACS recruited homosexual/bisexual men in 
1983-1984 and has studied them twice yearly by physical examination and laboratory testing. 
HIV-1 seropositivity was defined as a positive enzyme-linked immunosorbent assay (ELISA) 
and a Western blot with bands corresponding to at least two of the Gag, Pol, and Env proteins of 
HIV-1. Multiple Gag (p17, p24), Nef and Env (C2-V5) sequences were derived at 6 month 
intervals over the course (>10 years) of infection, with the earliest sequences sampled at 4 
months following seroconversion [294], were used for this analysis. A healthy, HIV-1 
seronegative, HLA matched (A*0201 and B*0702) individual was used for comparison. 
 
Analysis of T cell phenotypes 
The MACS routinely collects lymphocyte phenotype data at bi-annual visits. Briefly, 
lymphocytes are gated on CD45 (PerCP) and then analyzed for CD3+(FITC), CD4+(PE) or 
CD3+(FITC), CD8+(PE) cells were stained according to previously described methods using 
antibodies obtained from Becton Dickinson Immunocytometry Systems (San Jose, CA). 
Unstained cells and isotype-matched, control antibodies were used for accurate discrimination of 
positively staining from negatively staining cells. All analyses were carried out on an EPICS XL 
flow cytometer (Coulter Electronics, Hialeah, FL) and 5000 lymphocytes were analyzed from 
each sample. 
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Synthetic Peptides 
Overlapping 15-mer peptides spanning Gag, Nef, and Env (C2-V5) sequences of HIV-1, each 
overlapped by 11 amino acids representing the ‘founder strain’ [294] and evolving variants 
(Colleton unpublished, [373]).  Potential epitopes were targeted based on predicted binding 
scores (BIMAS), previously published, as well as, trends discovered that support CTL loss of 
reactivity due to evolving variants. Peptides were made at ResGen Invitrogen Corporation 
Huntsville, AL or SynBioSci Corporation Livermore CA). 
 
Dendritic cells (DC) 
To obtain immature DC (iDC), CD14+ monocytes were positively selected from cryopreserved 
peripheral blood mononuclear cells (PBMC) of MACS participant #8 after 3 years on ART using 
anti-CD14 monoclonal antibody (mAb)-coated magnetic beads (Miltenyi, Auburn CA) for a 
purity of >95%. The cells were cultured for 5 days in RPMI-1640 (Gibco, Grand Island NY) 
supplemented with 10% Fetal calf serum (FCS) (Cellgro) containing 1000U/ml recombinant 
granulocyte-monocyte colony-stimulation factor (GM-CSF) (Amgen, Seattle WA) and 
1000U/ml of recombinant human interleukin (hIL)-4 (R&D Systems) adding fresh cytokines 
every other day. On the 5th day, the iDC were harvested and reset at 1x106/ml and maturation 
factors were added for 40 hours [CD40L (0.5ug/ml Amgen) for ELISPOT assays and CD40L 
(0.5μg/ml) + IFNγ (1000U/ml; R&D Systems)] for primary stimulations. 
 
Priming of naïve T cells 
For this work, a primary T cell response was defined operationally as the production of IFNγ by 
T lymphocytes derived from PBMC of an individual who was not infected with HIV-1 (i.e., 
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HIV-1 seronegative), in response to four weeks of in vitro stimulation with DCs loaded with a 
specific HIV-1 peptide that was significantly greater than the response of these T cells to 
medium alone. For these T cell priming studies, I used freshly obtained PBMC from an HLA-
A*0201, B*0702 HIV-1 negative subject from the MACS, and cryopreserved PBMC from 
MACS participant #8 that were originally obtained 2 years prior to seroconversion. The T cells 
were cultured in RPMI 1640 medium (Gibco) supplemented with 10% fetal calf serum (FCS) 
(Cellgro) with peptide-loaded DC at a responder-to-stimulator (T/DC) ratio of 10:1. For peptide 
loading, mDC were incubated in medium (RPMI-1640) without supplemental serum containing 
50μg/ml of HIV-1 peptide for 2 hours in 370C, 5% CO2 atmosphere. Ag-loaded DC were then 
harvested and re-suspended with PBMC depleted of monocytes. Co-cultures were fed with fresh 
medium supplemented with recombinant IL-15 (2.5ng/ml; Peprotech) and IL-2 (50 U/ml; 
Chiron, Emeryville CA) after the first 5 days and there after. Secondary stimulations (boost) with 
Ag-loaded DC were added directly to cultures after peptide-pulse (2 hours) and then harvested 
after 28 days for functional readout (Figure 22).  
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Figure 22. Schematic depiction of the method for primary (in blue across the top of the 
cartoon) and memory (in purple across the bottom) T cell stimulation. Briefly, iDC are 
matured with immunomodulating factors for 40 hours, then used as APC for either (i) memory 
stimulation in which case peptides are loaded onto the mDC for 2 hours and then used in an 
overnight ELISPOT assay with PBMC, or (ii) primary stimulation in which peptides are loaded 
onto mDC and co-cultured for 4 weeks and then assayed by ELISPOT, Chromium release, or 
tetramer staining. 
 
 
Stimulation of memory T cells 
Memory T cell responses were defined operationally as the production of IFNγ by T 
lymphocytes derived from PBMC of an individual who was infected with HIV-1 in response to 
overnight stimulation with DC loaded with a specific HIV-1 peptide that was significantly 
greater than the response of these T cells to medium alone. To assess memory T cell responses to 
HIV-1 peptides, cryopreserved PBMC were obtained from the Pittsburgh MACS repository and 
thawed using the AIDS Clinical Trials Group procedures. The PBMC were routinely >80% 
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viable by a trypan blue dye exclusion method. The PBMC were suspended to a final 
concentration of 1x105 cells per microwell in RPMI 1640 cell culture medium with 10% fetal 
calf serum (FCS) for the overnight ELISPOT assay. 
 
ELISPOT 
The 96-well plates (Millipore, Billerica, MA) were coated overnight at 40C with 5μg/ml anti-
interferon-γ (IFNγ) monoclonal antibody (Mabtech, Stockholm, Sweden). The antibody-coated 
plates were washed 4 times with PBS and blocked with RPMI supplemented with 10% FCS for 1 
hour at 370C. Responder cells were stimulated overnight with peptides (10μg/ml)-loaded DC at a 
ratio of 10:1 in 370C, 5% CO2 atmosphere. After development of the spots, the plates were 
counted with an Elispot reader system (Cell Technology, Columbia, MD).  Data were expressed 
as net IFNγ spots per 106 cells. The number of spots/106 responder cells stimulated with HIV-1 
antigen expressing APCs minus number of spots/106 responder cells stimulated with antigen-
negative APCs. SEB was used as a positive control and 2 standard deviations over background is 
shown. 
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 Results 
Subject #8 is a Pittsburgh MACS participant whose virus was extensively analyzed for 
divergence and diversity in our previous investigation [294]. He had documented seroconversion 
to HIV-1 during our 6 month biannual follow-up approximately 2 years after enrollment in the 
study. He was chosen for this study because of availability of PBMC from pre-seroconversion 
through late disease progression and during subsequent suppression of HIV-1 infection on 
therapy. The natural history of HIV-1 infection in MACS participant #8 is shown in Figure 20, 
demonstrating a typical early rise in HIV RNA levels and a decline in CD4 counts, while CD8 T 
cell numbers increased over disease progression until the initiation of ART (>7 years). Viral 
suppression was achieved on ART while there was a gradual increase in CD4 T cell counts, and 
concomitantly CD8 T cells decreased.                                 
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Figure 20.  Natural history of HIV-1 infection in MACS participant #8. T lymphocyte counts 
and HIV-1 copies over course of disease progression are shown: CD3 (yellow triangle), CD4 
(red circle), CD8 (green diamond), RNA copies (open square). 
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Detection of memory CD8+ T cell responses to autologous virus 
Previously, bulk CTL lysis to Gag, Pol and Env was determined for this MACS participant using 
vaccine vectors expressing proteins of laboratory strain HIV-1 HXB2 [296] (Figure 21).  
YEARS OF HIV INFECTION
-4 -2 0 2 4 6 8 10
N
ET
  C
TL
m
-B
U
L
K
  (
 %
  L
Y
SI
S 
)
0
20
40
60
80
GAG
POL
ENV
AZT, 3-TC
Bactrim
Fluconaz.
Ketoconaz.
 
Figure 21. CTL lysis of previously published work [296] demonstrating reactivity to Gag (red 
circle), Pol (yellow triangle) and Env (green square) over years of infection. Seroconversion is 
shown as the leftmost vertical dashed line and time zero (0), and the time of CD3+T cell 
inflection point is marked by the another dashed line to the right. 
  
The strongest CTL activity was detected against Pol, and Gag, and less so to Env, shortly after 
seroconversion. These responses decline precipitously by the second year. I hypothesized that the 
less-than-robust CTL activity directed to Env was due, at least partially, to the recombinant 
vaccinia virus expressing HXB2 strain of HIV-1 that was used as a target. Hence, it was highly 
divergent from the individual’s sequences, thus underestimating the CD8+ T cell response.  
Therefore, I first determined the IFNγ response of memory CD8+ T cells to autologous 
‘founder’ strain Gag (p17 and p24), Nef and Env (C2-V5) and evolving variants to adequately 
address the host’s response to his quasispecies over disease progression, which our previous 
studies could not determine. The ‘founder’ strain and evolving variants that were identified from 
previous analysis of predicted MHCI epitopes corresponding to HLA-A*0201 and B*0702 
(Colleton unpublished). For autologous memory T cell responses, I used PBMC that were 
cryopreserved at sequential years during progressive disease and after the participant went on 
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therapy. The IFNγ ELISPOT results show a large number (breadth of response) of epitopes 
targeting to the relatively conserved sequences of Gag (Figure 23A), and Nef (Figure 23B), and a 
divergent Env (C2-V5) region (Figure 23C).  The greatest number of IFNγ responses where 
directed toward Nef when results are analyzed using the greater than 2 standard deviations from 
background and having greater than 50 spots per million (Figure 24). Cumulatively, the greatest 
number of IFNγ spots per million was seen directed towards Gag (Figure 25) when compared to 
the other two proteins (P<0.001). 
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Figure 23. Autologous 9- and 10-mer epitopes and 15-mers overlapping by 11 amino acids comprising Gag, Nef and Env regions of HIV-1 were 
singularly pulsed to DC matured with CD40L and cultured with PBMC from early, late and on ART visits were assayed in a standard overnight ELISPOT 
assay, to detect Ag-specific CD8+ T cell responses to autologous ‘founder’ and evolving variants of Gag (A), Nef (B) and Env (C) at early (solid black), 
Late (horizontal hatched) and ART (diagonal hatched).
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Figure 24  Total number of IFNγ ELISPOTS directed to Gag, Nef and Env displayed in  the three 
time points of  Early, Late or on ART.  
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Figure 25. Total positive CD8+ memory T cell responses at early, late and on ART time points of 
Gag, Nef and Env were compiled to compare the magnitude of IFNγ spots/106 between proteins. 
P<0.001=***, P<0.01=**, P<0.05=*. 
     
The number of total responses at different time points (e.g. early, late and on ART) were directed 
toward Gag, Nef and Env. I believe that the use of autologous viral peptides allowed for 
enhanced detection of these T cell responses when compared to chromium release assay data. 
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Detection of primary CD8+ T cell responses 
Previously, I developed an in vitro priming model (Colleton, unpublished) that was modified 
from our previous model and those of other research groups [71,208,242,243]. This new system 
can stimulate naïve T cells using immunodominant HIV-1 epitopes and 15-mer consensus strain 
peptides that had been loaded into DC (Colleton, unpublished). Then I exploited the availability 
of autologous cryopreserved PBMC (Figure 26) from >1 year prior to HIV-1 detection as our 
source of naïve CD8+ T cells.  
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Figure 26. Schematic course of disease progression depicting PBMC used to compare primary 
and memory T cell response. Memory T cell responses were defined as IFNγ production by 
PBMC obtained at early, late and on ART visits using an overnight ELISPOT assay. The 
primary responses were defined as IFNγ production by PBMC derived from pre-seroconverison 
samples, stimulated for over 4 weeks. Monocytes for generating md-DC were obtained from a 
late ART visit.  
 
 
Monocyte-derived (md)-DC were generated from autologous CD14+ monocytes from PBMC at a 
later visit (on ART for 3 years), and then loaded with founder (infecting virus sequences) and 
variant peptides representing sequences of MHCI restricted motifs of autologous HIV-1 obtained 
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at different times after of disease progression. For each known or predicted MHCI epitope in the 
founder virus, I assessed the “family” of variants that evolved over time within this viral RNA 
sequence under immunologic pressure in the absence of ART. After two rounds of stimulation 
and four weeks of co-culture CD8+ T cell responses were determined by the use of a standard 
ELISPOT assay. The results show that Ag-specific responses were detected against all three 
regions (Gag (p17 and p24), Nef, and Env (C2-V5)). Significantly greater, (P<0.01), primary 
CD8+ T cell responses were detected compared to memory T cell responses of early, late, and on 
ART visits (Figure 27).  
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Figure 27. All positive CD8+ T cell memory responses (defined as > 2 SD over background 
control) comprising early, late and on ART time points to Gag, Nef and Env (black circles) were 
compiled to compare the magnitude of IFNγ spots/106 and how they compared to primary 
responses (green circles) between proteins (P<0.001=***, P<0.01= **, P<0.05=*). 
 
 
As expected, memory T cell responses to a repertoire of early and late HIV-1 epitopes of Gag, 
Nef and Env were detected at the early visits, but were no longer detected at the late progression 
visits (representative results, Figure 28). Thus, the latter peptides are  
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Figure 28. Representative depiction of memory T cell responses compared to primary T cell 
responses to evolving variants of three Gag, Nef and Env epitopes detected by ELISPOT. 
Primary responses are labeled in green, memory responses are labeled as in previous graphs. 
Brackets are shown to separate the early/founder and late peptides. 
 
 
 
considered ‘immune escape’ variants by definition.  A limited number of memory T cell 
responses to early and late HIV-1 epitopes from all three proteins were recovered during ART. 
However, it is evident that primary T cell responses were detected to some late Gag, Env and 
Nef immune escape variants that did not stimulate memory T cell responses in the late 
progression or on ART time periods. 
This in vitro study supports the concept that ex vivo engineering of autologous Ag-loaded 
DC that are re-administered to HIV-1 infected person’s could enhance primary CD8+ T cell 
responses to immune escape variants of HIV-1 and potentially provide natural viral suppression. 
To further evaluate the immunogenicity of viral immune escape peptides derived from MACS 
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subject #8, I used a MACS seronegative HLA-A*0201, B*0702 donor with cryopreserved 
PBMC and fresh autologous DC matured with CD40L + IFNγ to compare primary responses. I 
found that the primary responses (Figure 29A-C) were directed at all three proteins (Gag, Nef 
and Env). MACS participant #8 overall had more responses than the control HLA matched donor 
(HLA-A*0201 and B*0702). The primary responses were directed to epitopes in the founder 
strain (early) and to evolving variants (late and on ART time points). 
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Figure 29. Autologous 9- and 10-mer epitopes and 15-mers overlapping by 11 amino acids comprising Gag, Nef and Env regions of HIV-1 were 
singularly pulsed to DC matured with CD40L and cultured with PBMC from early (solid black), late (horizontal hatched) and on ART(diagonal hatched) 
visits were assayed in a standard overnight ELISPOT assay (IFNγ spots/10^6), to detect Ag-specific CD8+ T cell responses to autologous ‘founder’ and 
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 However, the magnitude of the primary IFNγ response to Gag was similar between this donor 
and MACS participant # 8 (Figure 30). In contrast, responses to Nef and Env were  
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Figure 30. Total positive IFNγ responses detected for memory (black circles) and primary T 
cells(green circles) for MACS participant #8. A seronegative HLA-A*0201, B*0702 matched 
donor was used as a control (red circles).  P<0.001=***, P<0.01=**, P <0.05=*. 
 
significantly lower than for participant #8 (P<0.001). This is in part likely due to differences in 
priming by peptide specific for non-matched MHCI haplotypes between these persons. Also, 
individual genetic differences in the TCR repertoires could relate to preferential primary T cell 
responses to different epitopes. Overall, the data from these two primary T cell responses to 
HIV-1 Gag, Nef and Env peptides demonstrated showed 11% concordance (same epitope 
between to priming experiments) (Figure 31) among the reactive epitopes (e.g. IFNγ positive 
responses). 
 105
                              
Summary of primary T cell responses to HIV-1 
autologous Gag, Env and Nef peptides
32%
23%
C
N
11%
89%
Concordance = 17/159
HLA-A*0201, B*0702 matched
Concordant
Discordant
 
Figure 31. Summary of concordance in positive T cell responses between the HLA-A*0201, 
B*0702 matched individual and MACS participant #8. 
 
Discussion 
Progressive CD4 T cell depletion, with disproportionate declines in naïve CD4+ and 
CD8+ cells, characterizes untreated HIV-1 disease [374,375]. The underlying mechanisms of 
dysfunction can be attributed to direct cytopathic effects of viral replication on T cells, T cell 
homeostasis, phenotypic alterations of T cell subsets, accelerated apoptosis, and peripheral 
cytokine-dependent T cell expansion, all which remain poorly defined in HIV-1 disease [376-
378]. As our understanding of chronic infections increases, new therapies, such as ART, have 
allowed HIV-1 infected individuals survival, but persistent viral reservoirs remain. Although 
management of HIV-1 disease depends largely on the degree of viral load suppression, there are 
many unanswered problems revolving around to what extent immune function is reconstituted 
[60,327-336] while on drug.  
The recovery of CD4+ T cells in HIV-1 infection during ART has been attributed to the 
production of naïve T cells associated with the thymus [339-342] while the recovery of naïve 
CD8 T cells (CD8+ CD45RA+ CD62L+) [335,336] remains controversial [123,349]. Particularly 
noteworthy, however, is the detection of phenotypically naïve T cells in athymic mice and 
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humans, suggesting that extra-thymic pathways of T cell development exist [350,351,354].  I 
hypothesize that residual memory T cells during ART that are specific for HIV-1 inadequately 
control replication of HIV-1 immune escape variants. Therefore, I further hypothesize that 
control HIV-1 infection and viral immune escape variants during ART requires priming of naïve 
CD8+ T cells specific for these variants. 
Previously, bulk CTL lysis to Gag, Pol and Env from this MACS participant [296] 
revealed a strong CTL response to Pol and Gag, with less T cell reactivity to Env. The drop off 
in reactivity to Env that was seen could be due to the extensive diversity of these viral sequences 
evolving over disease progression, thereby underestimating the CD8+ T cell responses. In the 
present study, the loss of memory CD8+ T cell reactivity to evolving quasispecies of HIV-1 was 
defined as immune escape.  With that understanding, I determined the IFNγ response of memory 
CD8+ T cells to the autologous ‘founder’ strain of Gag (p17 and p24), Nef, and Env (C2-V5), 
and the evolving variants at different time points during disease progression (e.g. early, late and 
on ART). I sought to determine if loss of CTL responses that were seen during progression, were 
recovered on ART.  
The IFNγ results show a large number (breadth of response) of epitopes targeting to the 
relatively conserved sequences of Gag, and Nef, and to the more divergent Env (C2-V5) region. 
Cumulatively, the greatest number of IFNγ spots per million cells was directed towards Gag 
compared to Nef and Env (C2-V5) (P<0.001), but the number of total memory T cell responses 
was greater to Nef and Env (C2-V5). Although definitive comparisons to peptides of laboratory 
strains of HIV-1 were not possible, the use of autologous viral peptides could have allowed for 
enhanced detection of T cell responses to these three proteins. As expected, there was a loss of 
memory T cell responses to the evolving variants of Gag, Nef and Env late in infection. The 
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basis for this loss of T cell reactivity is unknown. However, the loss of T cell reactivity to these 
epitope variants was not strongly related to loss of binding affinity for their two HLA haplotypes, 
HLA A*0201 and HLA B*0702 (Colleton unpublished). Other possible mechanisms for the loss 
of memory T cell responses that remain to be elucidated in this model include changes in 
proteolytic processing of the MHCI peptides, anergic T cell reactivity due to poor TCR signaling 
and post-signaling pathways (e.g., low cytokine or lytic granule production), loss of T cell 
coreceptor expression, and changes in PD-1/PD1L expression.  
Most importantly, my data show that naïve CD8+ T cells from the same individual who 
lost memory CD8+ T cell reactivity were able to be primed to autologous HIV-1 immune escape 
variants in vitro. This shows for the first time that it is potentially feasible to induce CTL to 
immune escape variants. Based on these priming results, it is unlikely that the peptide variants of 
immunodominant epitopes were unable to bind to their MHCI restriction molecules (Colleton, 
unpublished). It is also possible that our long-term in vitro priming model is more sensitive at 
detecting subdominant epitopes than the overnight memory T cell ELISPOT assay. Nevertheless, 
these data show that viral “immune escape” cannot be generalized across all epitopes, in that loss 
of memory T cell reactivity to an “immune escape” variant does not necessarily equate with lack 
of capacity of this variant to prime T cells.   
Previously, it was demonstrated that DC matured with CD40L, and subsequently loaded 
with immunodominant HIV-1 peptides [242] or apoptotic bodies [211] can activate residual 
HIV-1 specific memory responses while on ART. I propose that targeting immune reconstituted 
naive CD8+ T cells through immunotherapy should enhance CD8+ T cell responses, and by 
exploitation of the DC ability to instruct the T cells to mount a robust and broad response HIV-1 
antigens is the target for immune control of this chronic viral infection [164,368-372].  
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Currently, immunotherapy studies have used consensus strain HIV-1 antigens which 
inadequately represent the host’s diverse pool of HIV-1 quasispecies (Colleton, unpublished). 
My study supports the concept of using autologous virus as antigen to represent the host’s 
diverse pool of quasispecies in immunotherapy to enhance CD8+ T cell responses. My data show 
that use of DC loaded with peptides representing autologous HIV-1 sequences can expand 
memory and primary T cell responses in vitro. This is also the first study directly comparing 
memory and primary T cell responses to a virus using cells from the same individuals, and 
provides a model for future analysis of these basic host immune functions. Finally, my data show 
a potential advantage for immunotherapies using these approaches with autologous virus 
representing a large repertoire of the host’s diverse HIV-1 antigen pool. This could elicit the 
most specific primary immune response for each patient’s quasispecies of HIV-1, giving the 
broadest immune control of HIV-1 infection during ART. This could allow for ultimate goal of 
immune control of HIV-1 infection in the absence of ART. 
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VI. CHAPTER SIX: OVERALL DISCUSSION 
 
Overview of the rationale for this doctoral research 
Although it has been almost 25 years since the identification of the causative agent of 
AIDS [2,3], we still struggle to understand the dynamics of viral-host interactions leading to 
progressive disease. The HIV-1 epidemic continues, with the latest statistics estimating more 
than 40 million individuals are living with HIV-1 [391]. These individuals reside chiefly in less 
fortunate countries where a large portion of the population does not even have access to adequate 
medical care, let alone ART. The global need for an effective vaccine against HIV-1 is critical. 
This doctoral research study contributes to the development of our knowledge of viral 
immunogenicity and enhancing T cell responses towards successful immunotherapy and viral 
control. 
It is known that the infidelity of the reverse transcriptase (RT) of HIV-1 [148] and the 
rapid turnover [154] quickly diversifies the virus population within an individual, as well as, the 
circulating clades identified (A-J currently) [390] in geographical populations. Of all the HIV-1 
genes, Env, and particularly its V1-V5 domains, demonstrate the greatest amount of 
heterogeneity [146,147]. One of the hallmarks of HIV-1 infection is its high level of genetic 
divergence over time, which accumulates into what is termed the quasispecies within an 
individual. The substantial genetic changes of HIV-1, within a host, are driven by not only the 
error-rate of the RT, but the host genetic background as well. Mutations within a CTL epitope 
can have dynamic change in processing, presentation and recognition of that epitope. Viral 
sequence changes can have an effect in the capacity of viral peptides once processes, to bind to 
MHCI molecules, which in turn could result in altered recognition and response by CD8+ T cells.  
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Conclusions and importance of the research findings. 
Specific Aim 1:  Identify potential MHC class I CD8+ T cell epitopes in autologous HIV-1 
sequences of MACS participant #8.  
I hypothesize that the loss of anti-HIV CTL activity could be due to changes in the CTL epitopes 
that arise in the variant quasispecies, specifically in their MHC class I (MHCI) binding capacity 
and impacts disease progression (e.g. CD4+ T cell counts and viral load).  
Therefore, the first aim of this project was to examine the MHCI binding affinities of 
peptides that we had derived from Gag, Nef and Env quasispecies of an HIV-1 infected 
individual. Notably, there are other parameters that can be considered when assessing affects on 
CD8+ T cell recognition such as proteasomal cleavage sites [300-303] and TAP binding patterns 
(Predict [304]). However, these types of analyses were beyond the scope of this project. Instead, 
I focused on identifying potential CTL epitopes and their subsequent binding affinities to MHCI 
molecules, which can be viewed as one of the major factors affecting antigen presentation to 
CD8+ T cells that is impacted by genetic diversity of the antigen.  
To determine potential CTL epitopes, I used the in silico program BIMAS, which is an 
interactive MHCI binding prediction algorithm, to analyze the evolving autologous HIV-1 
sequences over the course of disease progression for MACS participant #8. Recently this 
algorithm was compared to many others that are available on-line [234], and BIMAS ranked 
very high for the two haplotypes, A*0201 and B*0702, that we used in this study. I was able to 
demonstrate that the predicted binding scores to MHCI epitopes of variants evolving from the 
founder strain have three basic patterns: (i) weaker (or decreasing), (ii) neutral (or constant), and 
(iii) stronger (or increasing) that evolved in the quasispecies over disease progression.  
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I then assessed actual binding of the autologous HIV-1 peptides to MHCI to evaluate the 
accuracy of the BIMAS prediction method. For this, I first tried to determine the binding affinity 
of these peptides using T2 cells [279, 280], which are TAP deficient cells expressing HLA-A2, 
but this method was insensitive. Therefore, I turned to a soluble MHCI binding assay using 
fluorescent polarization methods in competitive binding analysis [290,298] for higher throughput 
potential, as well as greater sensitivity than the T2 cell method. I confirmed some of the 
predicted binding patterns using this MHCI binding assay for epitopes restricted to HLA-A*0201 
and B*0702, and demonstrated a range from non-binding to strong affinity. However, to make 
definitive conclusions about MHCI binding and HIV-1 disease progression, further assessment 
of additional potential epitopes that were determined to have strong correlative values (R2>0.5) 
between predicted MHCI binding and CD4+ T cell counts or to viral load are needed. 
It was especially interesting to see an accumulation of strong associations for the 
predicted binding trend that increased in strength during disease progression. This has been noted 
in other studies [199] and may be an escape mechanism where the higher binding affinity 
epitopes are selected due to their low disassociation rate and ineffective control on viral 
replication. Most of the MHCI binding results on the peptides that were selected for testing were 
in the neutral category. Thus, there was no significant relationship between predicted and true 
binding of HIV-1 peptides to MHCI, or to disease progression overall. However, the prediction 
scores for the Nef epitopes and their variants demonstrated a strong correlation to actual binding 
affinity (R2= 0.7948). Indeed, HLA-A*0201 predicted binding scores (R2=0.6222) correlated 
much stronger than B*0702 (R2= 0.1537) to actual binding affinities. 
Numerous putative antigenic and immunogenic peptides have been identified through this 
method of reverse immunology. The identification of CD8+ T cell defined antigens has improved 
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over recent years, as our capacity to predicting MHCI binding for the most common HLA 
variants among the population has accumulated more experimental data. However, to use in a 
vaccine design, successful prediction for as many HLA variants as possible is necessary to 
increase coverage of the population. Accurate prediction modeling as an approach to evaluating 
MHCI epitopes binding and immunogenicity are desired to lower the high cost and labor 
intensive nature of such studies. 
 
Specific Aim 2: Develop an in vitro priming model to evaluate potential binding of MHC 
class I CTL epitopes. 
I hypothesize HIV-1 peptide antigen loaded, mature dendritic cells have the capacity to prime 
naïve CD8+ T cells in an in vitro system. To address this, I will define the best in vitro priming 
model for inducing primary responses of naïve CD8+ T cells in HIV-1 seronegative individuals. 
Over the past decade, major improvements in our understanding of what constitutes the 
memory T cell response have revolutionized the field [86,87,91,92]. However, researchers are 
still trying to ‘spot’ an effective HIV-1 vaccine. As far as the technology has come, reliable 
surrogate markers of what constitutes “protection” to HIV-1 infection or is critical to impeding 
HIV-1 disease progression has not been identified. In fact, novel immunotherapeutic vaccines are 
being developed in the wake of our present inability to develop a preventative HIV vaccine.  The 
ideal vaccine would establish ‘sterilizing immunity’ however, the best expectation presently is a 
therapeutic vaccine; one that can bolster existing immune responses to keep up with the evolving 
virus. The basic rationale for DC immunotherapy in HIV-1 infected persons is to instruct the T 
cell responses to function more effectively to resemble the T cell responses of a long-term 
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nonprogressor (LTNP) or elite controller. However, utilizing DC as a vehicle to overcome 
immune dysfunction is a difficult challenge. The primary objective is to elicit a strong Th1 
response to enhance CD8+ T cell responses due to the evidence that supports the importance of 
virus-specific CD8+ T cells. The supportive data are multifaceted: (1) peak virus-specific CD8+ T 
cell activity coincides with the decline in virus during acute infection [380,381], (2) CD8+ T cell 
depletion studies in the SIV model leads to increased virus levels [51,85], (3) infusion of virus-
specific CD8+ T cells leads to decreased viremia [382] and (4) viral escape leads to increasing 
viral loads [105,143,191,192,383-387]. 
Based on this literature, I proposed that a broad and robust primary CD8+ T cell immune 
response is important for an effective prophylactic or therapeutic vaccine. Priming of naïve CD8+ 
T cells has been shown to require three signals involving the MHCI/peptide complex on DC 
(signal 1) [245] along with the costimulatory molecules (e.g. CD80 and CD86) (signal 2) 
[74,246,247] on the surface of DC which activate CD8+ T cells with the help of CD4+ T cells 
[107-109,248] and IL-12 (signal 3) [82,103,249-253,255,256,318-321].  Combining this 
knowledge of how DC work and the correlative value of HIV-1 specific CD8+ T cells being 
necessary for viral suppression, I explored the use of an in vitro primary stimulation model. I 
chose to examine CD40L and IFNγ, our most potent modulator of memory T cell reactivity to 
HIV-1 [219,388], compared to a TLR3-cytokine cocktail currently used in DC immunotherapy 
of cancer [220]. First I phenotyped md-DC to determine their expression for maturation surface 
markers; all three maturation groups expressed high surface marker levels of co-stimulatory 
ligands B7.1 (CD80) and B7.2 (CD86) on the DC surface for a strong signal 2, compared to iDC. 
Second, IL-12, is well known to augment CTL responses in experimental systems [323,324]. 
Reports have demonstrated that primary expansion can be obtained with signal 1 and 2, but 
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effector function and memory requires a third signal that can be provided by either IL-12 or type 
I interferons [83,84,322] and in the absence of this signal some cells can survive, but they are 
immunotolerant [103]. I therefore determined the cytokine profiles of the various DC maturation 
groups. Our results showed that all of the DC modulation groups produced IL-12.  However, iDC 
treated with CD40L + IFNγ produced the most IL-12(p40 and p70), which is critical for signal 
three in this model.  Furthermore, I demonstrated that this higher IL-12 production by the DC 
translated into the superior priming capacity CD8+ SL9(p17 77-85LAI) Tet+ cells. Further work is 
necessary, such as blocking of IL-12 by neutralizing antibodies, to prove that these high levels of 
IL-12 produced by the DC are critical to priming of the CD8+ T cells in this in vitro model.   
Based on this three signal priming model, I then demonstrated the capability of DC 
treated with CD40L + IFNγ to induce a broad spectrum of primary CD8+ T cell responses to five 
immunodominant HLA-A*0201-restricted epitopes. As expected based on the well known helper 
effects of CD4+ T cells, I found that CD4+ T cells were required for efficient priming of HIV-1 
specific CD8+ T cells. The primed CD8+ T cells exhibited HIV-1 peptide-specific cytolytic 
activity and IFNγ production that was optimized by the presence of autologous CD4+ T cells. I 
postulate that the CD4+ T cells provided the necessary IL-2 signals when a secondary stimulation 
is given [325]. 
Finally, naïve CD8+ T cells from two HIVneg HLA-A*0201 donors in the presence of 
CD4+ T cells with CD40L + IFNγ mDC for in vitro priming to consensus sequences of 
overlapping 15-mers to Gag, Env and Nef regions of HIV-1 were evaluated. I determined that 
both donors exhibited a broad immunogenicity (IFNγ production) for many well documented 
epitopes in the Los Alamos HIV database [393]. Moreover, the number of potential T cell 
epitopes that matched between the two donors was 34%. Using BIMAS prediction modeling 
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with the Los Alamos HIV Database [393], we identified many potential MHC class I binding 
epitopes for Gag, Env and Nef among the peptide regions that were positive for T cell reactivity 
in our priming system. Presently, I cannot rule out the possibility that some of these results are 
from CD4+ T cells due to the fact that I was unable to enrich CD8+ T cells for each of these 
responses. However, there are many known CTL epitopes within the 15-mers previously 
detected in functional assays by other groups [381], and predicted in BIMAS by us, thus 
supporting that the responses are CD8+ T cell specific. Confirmation that these are indeed CD8+ 
T cell epitopes, however, requires that they be mapped to their minimal, 9- and 10-mer MHC 
class I epitopes. 
In summary, in aim 2 I showed that a primary CD8+ T cell response to HIV-1 can be 
activated in vitro by stimulation of naïve T cells with HIV-1 peptide-loaded DC. The optimal 
primary T cell response to HIV-1 required maturation of the DC with CD40L + IFNγ, and IL-12 
and CD4+ T helper cells. The primed CD8+ T cells recognized multiple regions of Gag, Env and 
Nef that corresponded to known and predicted MHC class I epitopes. This in vitro priming 
model can be of importance in evaluation of various aspects of HIV-1 vaccines, including the 
immunogenicity of predicted and known MHC class I restricted epitopes.   
 
Specific Aim 3: Compare primary and memory response in MACS participant #8.  
I hypothesize that the change in HIV-1 epitopes due to CTL selective pressure will result in 
failure of priming of CD8+ T cells to late escape variants.  
On ART it is possible to enhance secondary and primary responses that may potentially 
help to control viral replication. Therefore, I applied the priming model established in specific 
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aim 2, exploiting the unique ability to compare primary naïve CD8+ T cells responses (pre-
seroconversion) to memory of early, late and ART time points during MACS participant #8 
progressive infection. 
Progressive CD4 T cell depletion, with disproportionate declines in naïve CD4+ and 
CD8+ cells, characterizes untreated HIV-1 disease [374,375]. The underlying mechanisms of 
dysfunction remain poorly defined in HIV-1 disease [376-378]. Management of HIV disease 
depends largely on the degree of viral load suppression, but there are many unanswered 
problems revolving around to what extent immune function is reconstituted [60,327-336] while 
on drug.  
 While the recovery of CD4+ T cells in HIV-1 infection during ART has been attributed to 
the production of naïve T cells that has been associated to the thymus [340-342,344-348], the 
role of naïve CD8 T cells (CD8+ CD45RA+ CD62L+) [335,336] remains controversial [123,349]. 
Particularly noteworthy, is the detection of phenotypically naïve T cells in athymic mice and 
humans suggesting that extra-thymic pathways of T cell development must exist [350,351,354].  
Researchers believe that the recovery of naïve CD8+ T cells during ART is critical to restoration 
of immune control of HIV-1 infection.  
Previously, bulk CTL lysis to Gag, Pol and Env from this MACS participant was 
determined [296], which demonstrated shortly after seroconversion, a strong CTL response was 
detected to Pol and Gag, while Env was only minimally reactive. I believe the drop off in 
reactivity to Env that was seen, was due to the diversity of the viral sequences evolving over 
disease progression, and thereby underestimating the CD8+ T cell responses. Therefore, in my 
last specific aim, I defined decreasing memory CD8+ T cell reactivity to evolving quasispecies of 
HIV-1 as immune escape.  I determined the IFNγ response of memory CD8+ T cells to 
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autologous ‘founder’ strain Gag (p17 and p24), Nef, and Env (C2-V5) and the evolving variants 
at different time points during disease progression (e.g. early, late and on ART) to determine if 
enhanced CTL response were seen. The IFNγ results show a large number (breadth of response) 
of epitopes targeting to the relatively conserved sequences of Gag, and Nef, and a divergent Env 
(C2-V5) region. Cumulatively, the greatest number of IFNγ spots per million cells was seen 
directed towards Gag when compared to Nef and Env (C2-V5) (P<0.001), but the number of 
total responses was directed toward Nef and Env (C2-V5). I believe the use of autologous viral 
peptides did indeed allow for enhanced detection of T cell responses. 
Most importantly, I showed that naïve CD8+ T cells from the same individual who lost 
memory CD8+ T cell reactivity were able to be primed to these autologous HIV-1 immune 
escape variants from PBMC previous to his seroconversion. This shows for the first time that it 
is potentially feasible to induce CTL to immune escape variants and although the basis for this 
reactivity is unknown, the loss of T cell reactivity to these epitope variants was not related to loss 
of binding affinity for their two HLA haplotypes, HLA A*0201 and HLA B*0702 (Colleton 
unpublished). It is also possible that our long-term in vitro priming model is more sensitive at 
detecting subdominant epitopes than the overnight memory T cell ELISPOT assay. Nevertheless, 
these data show that viral “immune escape” cannot be generalized across all epitopes, in that loss 
of memory T cell reactivity to an “immune escape” variant does not necessarily equate with lack 
of capacity of this variant to prime T cells.   
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Overall conclusions 
This research builds directly on 20 years of work on T cell immunity to HIV-1 in this 
laboratory. Previously, it has been demonstrated that DC matured with CD40L and subsequently 
loaded with immunodominant HIV-1 peptides [242] or apoptotic bodies [211] can activate 
residual HIV-1 specific memory responses while on ART. Therefore, I hypothesized that 
targeting immune reconstituted naive CD8+ T cells through immunotherapy should enhance 
CD8+ T cell responses, and by exploitation of DC it is possible to instruct the T cells to mount a 
robust and broad response to the chronic infection [164,368-372]. The current study has provided 
initial data that support our hypothesis that CD8+ T cells can be primed by in vitro engineered 
DC, even against HIV-1 peptides representing immune escape variants.  
Presently, immunotherapy studies have used consensus strain HIV-1 antigens and I 
believe that this inadequately represent the host’s diverse pool of HIV-1 quasispecies. This study 
supports the concept of using autologous virus as an antigen in immunotherapy. These data 
demonstrate that use of autologous viral sequences expands the memory and primary T cell 
responses in vitro. Thus, a potential advantage is that immunotherapies can use these approaches 
for autologous virus representing a large repertoire of the host’s diverse HIV-1 antigen pool. 
This could elicit the most specific primary immune response for each patient’s quasispecies of 
HIV-1, giving the broadest immune control of HIV-1 infection during ART. Such an approach 
has important public health implications in that it could have a strong positive impact on, and 
improve the control of, HIV-1 infection in HIV-1 infected persons on ART. It also serves as an 
in vitro model for development of prophylactic vaccines against HIV-1 and other infectious 
agents.  
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 PUBLIC HEALTH AND SCIENTIFIC SIGNIFICANCE 
 
 
The most recent global statistics according to the UNAIDS report are that more than 40 
million people are living with HIV. These individuals predominantly are in resource deprived 
countries such as Sub-Saharan Africa where access to health care and medicine is limited.  The 
infection rates have gone down in some of these countries such as Uganda, but remain high in 
many of the other regions such as Mozambique and Kenya. While preventative measures such as 
condoms and circumcision can help prevent infection, a prophylactic vaccine is essential to 
prevent further spread of HIV-1. The ideal T cell response induced by a prophylactic vaccine is 
one that can eliminate the pathogen before it has a chance to establish an infection, i.e., induce a 
‘sterilizing immunity’. Despite researchers best efforts in the past 25 years, however, we are still 
unable to provide an effective HIV-1 vaccine and are in fact struggling with surrogate markers 
that are correlative to protection for this virus.   
Unfortunately, such prophylactic vaccines will not help the millions of people who are 
already infected with the virus, and who face life-long treatment with expensive and toxic 
antiretroviral drugs. Currently, therefore, we believe that the best strategies for these individuals 
are therapeutic vaccines, in which the goal is to enhance T cell responses within an infected 
individual while on ART. The objective of this method is to attack residual viral reservoirs by 
expanding the individual’s HIV-1 specific, primary T cell responses to control virus replication.  
Thus the research done in this doctoral program on stimulation of CD8+ T cell responses 
to HIV-1 by antigen-loaded DC has direct, public health relevance for the development of both 
prophylactic and immunotherapeutic vaccines. Furthermore, the T cell priming model developed 
in this doctoral project opens many new possibilities to advance our knowledge of HIV-1 
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immunity, as well as immunity to other infectious agents. Indeed, this in vitro vaccination model 
for HIV-1 and potentially many other viruses is the only model besides the humanized mouse 
models that allows intricate dissection of the many variables of induction of T cell immunity in 
humans. These could include determining the role of many factors in priming of T cells, such as 
different antigen presenting cells, helper cells and suppressor cells, cell activation states, soluble 
and membrane-bound factors, and T cell epitope mapping and discovery for HIV-1 and other 
viruses.  
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VII. CHAPTER SEVEN: FUTURE DIRECTIONS 
 
While this dissertation has addressed a number of issues pertaining to enhancing T cell 
immunity, the field still has many questions that need to be addressed. The following sections 
discuss several questions that still need to be resolved and warrant further investigation. 
 
1. Examining the MHC class I prediction model. 
I have demonstrated in one individual that autologous viral sequences change, potentially 
effecting MHCI binding (e.g., the three binding trends). There was an accumulation of the 
increasing pattern in binding to MHCI potential, which has also been reported for SIV research. 
Therefore, this study will be expanded to include other MACS participants where autologous 
viral sequences are available and who have common haplotypes for at least two alleles and are 
listed in the Table 5. 
 
Table 5: MACS participants and their haplotypes. 
 
MACS Participant # Status HLA haplotypes 
1 Progressor A2, A2, B27 
2 Progressor A2, B27 
4 Progressor A2, A2 
5 Progressor A2, A2, B27, B7 
7 Progressor A2, B7 
12 LTNP A2, B27 
14 Rapid progressor A2, A2 
 
 
The Rinaldo laboratory will determine if associations on a larger scale could identify 
common epitopes amongst HLA matched individuals and whether associations can be seen for 
disease progression through a measure of these epitopes in relation to viral load and CD4 T cell 
counts. Due to the limitations of predicting binding epitopes, I was concerned with examining 
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many sequences that were in fact, not true epitopes. Therefore, binding affinity to soluble MHC 
was directed at previously published epitopes and their corresponding variants to determine the 
range of the fluorescent binding assay. Further binding affinities of MHCI epitopes representing 
the decreasing and increasing patterns need to be determined. 
 
2. In vitro priming model 
 
I determined the optimal epitopes that were primed to the consensus strain of Gag, Nef 
and Env experiments by using synthesized 9- and 10-mer peptides representing the ‘optimal’ 
epitope deduced by prediction modeling (BIMAS) in dose- response curves in order to determine 
if these epitopes are truly CD8+ T cell specific and are not attributed to CD4+ T cell responses. It 
is also important to look at the surface expression of primed CD8+ T cells to determine at which 
stage they have differentiated into (e.g. CD45RA/RO,CD28, CD27, CD57) as well as the 
cytokines other than IFNγ they are able to produce (e.g IL-2, CD107ab, perforin, granzyme AB). 
Next, under this model the Rianldo laboratory should explore the different dendritic cell 
immunomodulating factors I used to determine if there are any proliferation (CSFE) differences 
in the CD8+ and CD4+ T cells based on the maturation method. This information is critical as we 
begin to understand the different subpopulations of memory T cells and their contributions to 
controlling acute and chronic viral infections. The different dendritic cell immunomodulating 
factors used in this study need to be further assessed to determine if there are any proliferation 
(CSFE) differences in the CD8+ and CD4+ T cells based on the maturation method. This is an 
important issue central to the need of enhancing effective T cell responses while on ART for 
immunotherapy.  Having an in vitro priming model that is capable of evaluating immunogenicity 
in the context of proliferation, cytokine proliferation and memory surface markers expression 
would greatly aid in vaccine strategies. 
 123
Finally, it would be of value to expand this model to explore other dendritic cell 
populations, such as Langerhans cells and plasmacytoid dendritic cells, which could be directly 
targeted by immunotherapies in vivo. 
 
 
3. Primary and secondary memory responses. 
In my last specific aim, a novel concept was to compare primary and secondary memory 
T cell response within the same individual that was subsequently infected with HIV-1. To our 
knowledge this is the first time this has been done. Although I was able to show loss of anti-
HIV-1 CTL reactivity to some evolving viral variants (immune escape) and subsequent priming 
responses to these variants, more epitopes are needed to confirm and expand my major 
conclusion. This should include more epitopes and their variants to be tested in MACS 
participant #8 PBMC from the available specimens left as well as extending this study to 
examine more of the MACS participants. Implications for supporting the concept of using 
autologous HIV-1 sequences in immunotherapy to get the most robust, broad T cell responses 
expanded thereby, potentially controlling viral replication when ART is stopped is a central issue 
in treatment of HIV-1 infected individuals. 
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APPENDIX A: Evolutionary changes of 10-mers HLA-A*0201 
 
Yrs 
post 
SC
0.33
1.16
1.66
2.08
2.50
3.08
3.50
4.00
4.58
5.08
5.58
6.00
6.33
6.83
7.92
8.42
8.75
9.50
10.5
Viral evolutionary changes in HLA-A*0201 predicted binding scores of 10mers: 
subject #8 (HLA-A2, A24, B7, B40)
Gag-p17         Gag-p24                     Env C2-V5                      Nef
5-10
10-15
15-20
20-30
30-35
35-50
>=50
 
Figure 32: Scanning the impact of viral evolutionary changes on HLA-binding. 
Predicted binding to HLA-A*0201 10-mers across the genome over years following seroconversion, 
was mapped for sequences (Gag-p17, Gag-p24, Env, Nef) in subject #8. Each 10-mer amino acid motif 
in the sequence alignment was colored according to predicted HLA-binding score indicated in the score 
key. Each protein analyzed revealed a trend of three patterns: (i) increasing, (ii) decreasing, (iii) 
constant.  
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APPENDIX B: Evolutionary changes of 9-mers HLA-B*0702 
 
Yrs 
post 
SC
0.33
1.16
1.66
2.08
2.50
3.08
3.50
4.00
4.58
5.08
5.58
6.00
6.33
6.83
7.92
8.42
8.75
9.50
10.5
Viral evolutionary changes in HLA-B*0702 predicted binding scores of 9-mers: 
subject #8 (HLA-A2, A24, B7, B40)
Gag-p17         Gag-p24                     Env C2-V5                             Nef
5-10
10-15
15-20
20-30
30-35
35-50
>=50
 
Figure 33: Scanning the impact of viral evolutionary changes on HLA-binding. 
Predicted binding to HLA-B*0702 9-mers across the genome over years following seroconversion, was 
mapped for sequences (Gag-p17, Gag-p24, Env, Nef) in subject #8. Each 9-mer amino acid motif in the 
sequence alignment was colored according to predicted HLA-binding score indicated in the score key. 
Each protein analyzed revealed a trend of three patterns: (i) increasing, (ii) decreasing, (iii) constant.  
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APPENDIX C: Evolutionary changes of 10-mers HLA-B*0702 
 
Yrs 
post 
SC
0.33
1.16
1.66
2.08
2.50
3.08
3.50
4.00
4.58
5.08
5.58
6.00
6.33
6.83
7.92
8.42
8.75
9.50
10.5
Viral evolutionary changes in HLA-B*0702 predicted binding scores of 10-mers: 
subject #8 (HLA-A2, A24, B7, B40)
Gag-p17         Gag-p24                     Env C2-V5                             Nef
5-10
10-15
15-20
20-30
30-35
35-50
>=50
 
Figure 34: Scanning the impact of viral evolutionary changes on HLA-binding. 
Predicted binding to HLA-B*0702 10-mers across the genome over years following seroconversion, was 
mapped for sequences (Gag-p17, Gag-p24, Env, Nef) in subject #8. Each 10-mer amino acid motif in the 
sequence alignment was colored according to predicted HLA-binding score indicated in the score key. 
Each protein analyzed revealed a trend of three patterns: (i) increasing, (ii) decreasing, (iii) constant.  
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